aws Lisa Porfolio 2013

aws Hochtechnologie

Life Science Portfolio

2012/13

aws Life Science

Portfolio Austrian Life Science Companies

2013aws

Lif

e S

cience

Austria Wirtschaftsservice Gesellschaft mbH Walcherstraße 11A 1020 ViennaT +43 1 501 75-100 E [email protected] www.awsg.at

As the Austrian government pro-motional bank, austria wirtschafts-service is fulfilling the task of supporting Austria’s economy by funding companies and know-how transfer. The state-owned bank is particularly funding small and medium sized companies through guarantees, favorable credits, equity and other financial support. The aim of aws is to promote the setting-up of new companies, the growth of existing ones, regional development and the implemen-tation of innovation and technol-ogies. Our mandate ist to offer a broad range of company-related investments assistance programs, services and financing – from the pre-set up to the expansion and internationalization stages.

Furthermore the wide array of funding schemes avail-able to life science start-ups contributes to this thriving en-vironment. austria wirtschafts-service, the Austrian national promotional bank, provides financial support for start-up ideas for life-sciences through its funding pro-grammes ‘aws PreSeed’ and ‘aws Seedfinancing’. Furthermore, austria wirtschaftsservice imple-ments three initiative to close the financing gap for young, innovative companies. aws Busi-ness Angel fund provides co-financing for equity investments. It is aimed in particular at start-ups. aws ‘gründerfonds’ provides risk capital to companies with high growth

potential in the early stage as well as in the growth phase. These instruments are complemented by the Venture Capital initiative that undertakes

co-investments with institutional investors.

All these measures are now bearing fruit, creating new

and exciting jobs while securing Austria’s future

as a hot spot for inno-vation.

We hope to have captured your

attention for the aws Life Science Portfolio. It intends to provide you with more inside into the portfolio of aws funded Austrian life science companies, laying the ground for more investments into this burgeoning industry!

Mag.a Edeltraud StiftingerManaging Director Austria Wirtschaftsservice Gesellschaft mbH

Over the past decade, Austria has estab-lished itself as a well-respected hub of the life science industry. The growing life science sector is reflected in the increasing interest shown by international businesses in doing deals in Austria. The country is also proving to be an attractive location for oper-ations and significant inward investment for a number of multinational companies. These investments come on top of a whole series of international venture capital investments in Austrian life science.

What makes Austria an interesting place for the life sciences are the close links between solid academic research and outstanding medical practice, access to highly-skilled and dedicated scientists and managers, paired with an active start-up community, and last, but certainly not least, an extremely effective government support system for innovative companies.

The most innovative ideas in life sciences only make a difference once they have survived the journey from the laboratory bench to commercial launch. With aws LISA – Life Science Austria (LISA), austria wir tschaftsservice (aws), the Austrian government promotional bank,

Advance Austrian Life Sciences

Austria as an attractive location for a life science business is in constant global competition for the best ideas as well as the best innovation support system. aws produces statistics, analyses and stud-ies about the sector as a basis for key decision makers to offer them impetus for measures ensuring the competitiveness of the Austrian life science sector.

Fuel for Success

LISA International Marketing promotes the Austrian life science sector on the interna-tional stage and is the first point of call for enquiries relating to it. Marketing Austria as a life sciences location and making its scientific and business success stories more widely known gives the Austrian life sciences a higher profile, and contributes to Austria’s positioning in international mar-kets. We achieve our goal by maintaining a regular and high profile presence at the leading international life science conferenc-es and exhibitions (Medtech, Biotech and Pharma) and public relations. Furthermore, companies will be supported in obtaining follow-up financing as well as offering sector specific lectures. Life science en-trepreneurs can take advantage of insights provided by renowned specialists.

Finance New Ventures

Focusing on start-up ideas in biotechnol-ogy and medical devices, aws provides financial support through two custom-de-signed funding programmes: aws PreSeed and aws Seedfinancing. aws PreSeed pro-vides funding for the critical phase before a life science company is actually set up. Costs relating to the implementation of the science and the development of a busi-ness plan for a project can be funded with non-refundable awards of up to 200,000 Euro. aws Seedfinancing supports the start-up phase by providing up to 1 million Euro, combined with business advice. This Seedfinancing is then refunded when the company is making a profit or is sold.

Foster Entrepreneurial Spirit

As a way of fostering an entrepreneurial culture, we run the business plan compe-tition aws BoB – Best of Biotech, every two years. The goal of the competition is to motivate scientists and other creative individuals in the life sciences to translate their innovations into professional business plans by providing comprehensive and individualised coaching. Additionally they can win attractive cash prizes for the best business plan and the best business idea.Professional advice can mitigate the high risks encountered when a life science start-up is set up. That’s why on top of aws BoB – Best of Biotech, aws offers professional consulting and due diligence in the pre-start-up phase.

created a one-stop-shop support pro-gramme serving the whole value chain of a life science start-up. Comprised of four pillars – Foster, Finance, Fuel and Advance – LISA provides tailor-made support measures for every stage of development.

aws LISA – Life Science Austria

9092949698

100102104

— ugichem— Valericon— Valneva— Vela Laboratories— ViraTherpeutics— Xiber Science— XworX— Zytoprotec

Medtech

108110112114116118120122124126128130132134136138

*140142144146148150

— 4a medicom— AFreeze— Anagnostics— CVTec— Dioptex— DirectSens— EMCOOLS Medical Cooling Systems— EMTensor— Ergospect— impress— iSYS Medizintechnik— Jeder — Lacerta Technologies— medizinkraft solutions— Murmur Detect— mySugr— Ovula— ScarletRed— SIMCharacters— TissueGnostics— Tyromotion— VASCOPS— VASEMA

* Detailed information upon request.

Biotech/Pharma

AFFiRiS —Akron Molecules —

angothera —Annikki —

APEIRON Biologics —APEPTICO —

Avienne Pharmaceuticals —BDS Pharma —

Diagnosia —Dutalys —

Eucodis Bioscience GmbH —EveliQure Biotechnologies —

Evercyte —F-star —

GAT Microencapsulation —Haplogen —

Innovacell Biotechnologie —INOXIA Lifesciences —

Inte:Ligand —Lexogen —

Marinomed —Mucokinetica —

OrigImm —Panoptes Pharma —

PDC Biotech —Procomcure Biotech —

ProFem —RECARDIO —roombiotic —

Savira —SeaLife Pharma —

S-TARget therapeutics —TAmiRNA —

Themis Bioscience —The Siesta Group —

Tissue Med Biosciences —TUBE Pharmaceuticals —

182022242628

*303234363840424446485052545658606264666870727476788082848688

10 11

Cer

tain

infe

ctio

us a

nd

para

sitic

dis

ease

s

Neo

pla

sms

Dis

ease

s (D

.) of

the

bloo

d

and

bloo

d-fo

rmin

g or

gans

an

d ce

rtai

n di

sord

ers

invo

lvin

g th

e im

mun

e m

echa

nism

End

ocrin

e, n

utrit

iona

l an

d m

etab

olic

dis

ease

s

Men

tal a

nd b

ehav

iour

al

diso

rder

s

D. o

f the

ner

vous

sys

tem

D. o

f the

eye

and

ad

nexa

D. o

f the

circ

ulat

ory

syst

em

D. o

f the

res

pira

tory

sys

tem

D. o

f the

dig

estiv

e sy

stem

D. o

f the

ski

n an

d

sub

cuta

neou

s tis

sue

D. o

f the

mus

culo

skel

etal

sy

stem

and

con

nect

ive

tis

sue

D. o

f the

gen

itour

inar

y

syst

em

Pre

gnan

cy, c

hild

birt

h

and

the

puer

per

ium

Sym

ptom

s, s

igns

and

ab

norm

al c

linic

al a

nd

lab

orat

ory

findi

ngs,

no

t el

sew

here

cla

ssifi

ed

Indu

stria

l Bio

tech

nlog

y

Sup

ply

& S

ervi

ces

AFFiRiS I+II I

Akron Molecules PC PC+II

angothera PC+PM PM

Annikki X

APEIRON BiologicsPC+II

+IIIII II

APEPTICO II

Avienne Pharmaceuticals UD

BDS Pharma II

Diagnosia X

Dutalys UD UD

Eucodis Bioscience X

EveliQure Biotechnologies PC PC

Evercyte X

F-star PC

GAT Microencapsulation X

Haplogen PC X

Innovacell Biotechnologie III II

INOXIA Lifesciences PC PC UD

Inte:Ligand X

Lexogen X

Marinomed PC+M PC

Mucokinetica UD UD

BiotechPharma

I Clinical Phase I II Clinical Phase II III Clinical Phase III M MarketedPM PreMarket X ActivePC Preclinical Phase UD Under development

12 13

BiotechPharma

Cer

tain

infe

ctio

us a

nd

para

sitic

dis

ease

s

Neo

pla

sms

Dis

ease

s (D

.) of

the

bloo

d

and

bloo

d-fo

rmin

g or

gans

an

d ce

rtai

n di

sord

ers

invo

lvin

g th

e im

mun

e m

echa

nism

End

ocrin

e, n

utrit

iona

l an

d m

etab

olic

dis

ease

s

Men

tal a

nd b

ehav

iour

al

diso

rder

s

D. o

f the

ner

vous

sys

tem

D. o

f the

eye

and

ad

nexa

D. o

f the

circ

ulat

ory

syst

em

D. o

f the

res

pira

tory

sys

tem

D. o

f the

dig

estiv

e sy

stem

D. o

f the

ski

n an

d

sub

cuta

neou

s tis

sue

D. o

f the

mus

culo

skel

etal

sy

stem

and

con

nect

ive

tis

sue

D. o

f the

gen

itour

inar

y

syst

em

Pre

gnan

cy, c

hild

birt

h

and

the

puer

per

ium

Sym

ptom

s, s

igns

and

ab

norm

al c

linic

al a

nd

lab

orat

ory

findi

ngs,

no

t el

sew

here

cla

ssifi

ed

Indu

stria

l Bio

tech

nlog

y

Sup

ply

& S

ervi

ces

OrigImm PC

Panoptes Pharma PC PC

PDC Biotech I I

Procomcure Biotech PC

ProFem I PC+I

RECARDIO PC+II

roombiotic X

Savira PC

SeaLife Pharma PC PC PM

S-TARget therapeutics PC PC

TAmiRNA UD UD UD

Themis Bioscience I

The Siesta Group X

Tissue Med Biosciences UD PC UD

TUBE Pharmaceuticals PC PC

ugichem PC

Valericon PC PC

ValnevaPC+I+II

+III+M

Vela Laboratories X

ViraTherapeutics PC

Xiber Science PC PC PC

XworX X

Zytoprotec PC+II

I Clinical Phase I II Clinical Phase II III Clinical Phase III M MarketedPM PreMarket X ActivePC Preclinical Phase UD Under development

14 15

Medtech

Den

tal d

evic

es

Ele

ctro

mec

hani

cal

med

ical

dev

ices

Hos

pita

l har

dw

are

In v

itro

diag

nost

ic d

evic

es

Non

-act

ive

imp

lant

able

d

evic

es

Op

htal

mic

and

opt

ical

d

evic

e

Reu

sab

le d

evic

es

Sin

gle

use

dev

ices

Ass

istiv

e pr

oduc

ts fo

r p

erso

ns w

ith d

isab

ility

Dia

gnos

tic a

nd t

hera

peu

tic

radi

atio

n d

evic

es

Com

ple

men

tary

the

rapy

d

evic

es

Bio

logi

cal-d

eriv

ed d

evic

es

Sof

twar

e fo

r m

edic

al,

vete

rinar

y m

edic

al a

nd

e-he

alth

app

licat

ions

4a medicom IIb / PC IIb / PC

AFreeze III / A III / A

Anagnostics O / A

CVTec IIb / UD

Dioptex IIa+IIb / A IIa+IIb / A IIa+IIb / A

DirectSens IIa+III / UD IIa+III/UD

EMCOOLS Medical Cooling Systems I+IIa/A

EMTensor IIa / UD

Ergospect I / A I / A I / A

impress IIb / UD

iSYS Medizintechnik I / A I / A I / A I / A

Jeder IIa / A IIa / A IIa / A

Lacerta Technologies IIa / PC IIa / PC

medizinkraft solutions I / UD I / UD

Murmur Detect IIa / UD

mySugr I

Ovula IIa / UD IIa / UD

ScarletRed IIa / UD

SimCharacters O / UD O / UD

TissueGnostics I / A I / A

Tyromotion IIa / A IIa / A IIa / A IIa / A

VASCOPSIIb /

UD+PC+A

VASEMAI+IIa /

A+UD

I+IIa /

A+UD

A Approved O OtherPC Preclinical Phase UD Under development I Medical Device Class I IIa Medical Device Class IIa IIb Medical Device Class IIb III Medical Device Class III

16 17

Biotech / PharmaIn Austria, the life sciences — including biotech-nology and pharma — are viewed as being among the most important key technologies for driving forward new developments, and for developing economic potential. Over the last few decades a lively scene of innovative biotechnology / pharma companies has put Austria on the European life science map.

18 Biotech / Pharma – 19

AFFiRiSis an innovative biotechnology company based in Vienna. Using its proprietary AFFITOME® technology, it is able to develop customized peptide-based vaccines called AFFI-TOPES®, targeting chronic diseases with attractive market values and unmet medical needs. Indications include Alzheimer’s disease, Parkinson’s disease, atherosclerosis, diabetes, and several others.

Technology

— Indications: Alzheimer’s disease, Parkin-son’s disease, atherosclerosis, diabetes, dyslipidemia, and several others

— AFFITOME® is a fast and robust tech-nology that delivers a pool of synthetic peptide vaccines (AFFITOPE®) for the treatment of chronic diseases. Autoim-mune disease problems are avoided.

— AFFITOPES® mimic disease-associ-ated structures like certain structures of ß-amyloid in Alzheimer’s disease. AFFITOPE® vaccination in Alzheimer’s induces an antibody immune response to target pathologic derivatives of ß-amyloid.

Market

— The global Alzheimer’s disease market is forecast to increase from $ 5.3bn in 2011 to $ 14.3bn in 2020.

— The Parkinson’s disease market was $ 4.6bn in 2012.

— The diabetes market in US alone was $ 20bn in 2010 and is expected to reach $ 35bn in 2020.

— The cardiovascular and dyslipidemia market was $ 100bn in 2009 and is expected to increase to $ 130bn in 2020.

AFFiRiS product

Company Profile

Founded: 2003Legal Form: AGEmployees: 101

Management Team

CEO: Walter SchmidtCSO: Frank MattnerCTO: Arne von BoninCFO: Richard Westmoreland

Public Funding

aws: € 4.25MOthers: € 6.623M

Private Funding

€ 38.531M

AFFiRiS AG

Karl-Farkas-Gasse 221030 Vienna, Austria+43 1 798 157 530 [email protected]

Products Indication Stage of development

— AD02 Alzheimer’s Phase II

— AD03 Alzheimer’s Phase I

— PD01A Parkinson’s Phase I

— ATH01 Atherosclerosis Phase I

Products


Akron Molecules is a growing clinical-stage biopharmaceutical company founded in 2010. Akron strives to improve treatment options for conditions of high unmet medical need, with a current focus on chronic pain. The lead drug candidate, AKR 202, is on track to enter a clinical phase II study in pain asso-ciated with osteoarthritis (OA) in Q4’13, having obtained a regulatory “thumbs up” from a BfArM scientific advice meeting. Top-line data from the clinical study with AKR 202 in OA pain is expected in Q1‘15.

Company Profile

Founded: 2010 Legal Form: GmbH Employees: 7

Management Team

CEO: Henrik NilssonCSO: Shane McManusCAO: Lionel WightmanManaging Director: Manfred Reichl

Public Funding

aws Seed: Not disclosedFFG (Basis): Not disclosed

Private Funding

High single-digit million €

Technology

— Akron Molecules has developed a “drug repurposing” strategy, i.e. systematic identification of new uses for existing compounds.

— AKR 202 is a once-daily oral compound with a favorable safety profile, also when administered over the long term. Effi-cacy has been shown across a range of industry-standard rodent models of pain, demonstrating reduction of pain and inflammation plus potentially disease-modifying effects. AKR 202 represents a novel mechanism of action for the treatment of pain (purinergic receptor modulation and enzyme inhi-bition), with a potential for first-in-class status.

Market

— Pain affects approximately 1 billion people worldwide with an estimated annual market value of close to $30bn. There is a large unmet need both due to lacking efficacy and particularly safety concerns of current pain treatments (analgesics).

— The initial focus indication of Akron is chronic pain associated with OA (a type of nociceptive/ inflammatory pain—$4.4bn market size in 2010), followed by chronic lower back pain, as well as other important chronic pain indications, including postherpetic neuralgia.

New pain treatments by Akron

Akron Molecules GmbH

Helmut-Qualtinger-Gasse 21030 Vienna, Austria+43 1 23 604 [email protected]


— AKR 202 Pain (initially pain associated with OA) Phase II

— AKR 203 Pain Phase II

— AKR 210 Pain Preclinical

— AKR 101 Obesity/metabolic disease Preclinical

Products


angothera is developing treatments for mucosal immunoglobulin deficiency and its consequential diseases such as microbial infections. The first products are based on secretory antibodies from recombinant cell culture, plasma, or milk that are stable in the mucosa and can thus be given orally to patients.

Company Profile

Founded: 2012Legal Form: GmbHEmployees: 1

Management Team

CEO: Gottfried Himmler

Public Funding

aws PreSeed: € 200,000

Private Funding

€ 250,000

Technology

— angothera’s oral antibody technology can be used to produce either nutra-ceuticals from natural milk or glyco-engineered recombinant secretory antibodies.

— angothera is focusing on the develop-ment of products for mucosal immuno-globulin deficiency and its consequential disease.

— angothera is testing one of its prepara-tions for the prevention of Clostridium difficile–associated disease.

— angothera has filed IP on specifically glycosylated secretory immunoglobulins and their use.

Market

— Mucosal immunoglobulin deficiency has a prevalence of more than 0.3 % in the western population; in Europe and the US approx. 3 million people are affected. Mucosal immunoglobulin defi-ciency is largely undetected. Only the consequences of the disease such as recurring infections, allergies, and auto-immune diseases are treated with var-ying success.

— The annual costs of Clostridium diffi-cile infections for the health system in Europe are estimated to be more than 3 billion €. The additional costs per patient of C. diff. infection are estimated to be $ 2,000 to $ 90,000, depending on the severity of disease.

— angothera’s first product will be a nutraceutical that contributes to the maintenance of the normal function of the immune system and normal mucous membranes.


— Secretory Immunoglobulin Immunodeficiency with pre-dominantly antibody defects

preclinical

— Recombinant Secretory Component-Lewis

Immunodeficiency with pre-dominantly antibody defects

preclinical

— Secretory Immunoglobulin Enterocolitis due to Clostridium difficile

preclinical

— Sigavit Healthy mucosa pre-market

angothera GmbH

Donau-Oder Kanal IV SW 802301 Gross-Enzersdorf, Lower Austria, Austria+43 680 [email protected]

Products

Angothera technology


Annikki develops industrial technologies for the processing of chemical-grade cellulose, xylan for novel green polymers, xylitol, arabinose derivatives, lignin derivatives for high-per-formance polymers, green resins, and low-cost carbon fibers for high-volume applications. Annikki´s highly inte-grated process technologies enable superior yields of products and the production of numerous downstream products without the isolation of intermediate chemicals, thereby leading to unmatched economics.

Company Profile


Management Team

CEO: Ortwin ErtlCTO: Chris Prince

Public Funding

aws Seed: € 550,000FFG: € 4M

Private Funding

€ 3M

Technology

— Moderate temperature conserving lignin in natural state and avoiding byproducts such as furfural.

— Highly selective primary process yielding high purity product streams.

— Direct conversion of products from pri-mary process to downstream prod-ucts obviating costly isolation of intermediates.

— Proprietary and very efficient technology to separate C5 components xylose and arabinose and use them for individual processing.

— Technologies to make high quality lignin with excellent properties for further pro-cessing to high-performance polymers, green resins, and carbon fibers.

Market

— Addressing combined markets with current value of more than € 300 billion

— High-growth markets — Solution to CO2 issue — Green Chemicals — Green Polymers — Green Materials — Green Carbon Fibers for high-volume

markets — Food — Pharmaceuticals — Cosmetics

Products

— Chemical-grade cellulose for many applications like thickening agents, binders, adhesives, dispersing agents, film formers, water-retention agents, suspension aids, surfactants, lubricants, emulsifiers, stabilizers, excipi-ents, cellulose for rayon (viscose), etc.

Annikki GmbH

Rankengasse 288020 Graz, Styria, Austria+43 316 765 114 [email protected] www.annikki.at

Annikki laboratory

— Xylitol as non-carcinogenic, low-calorie sugar replacement product

— C5 chemical intermediates for diverse applications

— Green plastics at low cost — High-toughness polymers from lignin — Carbon fibers from lignin


APEIRON Biologics focuses on biological and immunological treatments of cancer. Its portfolio consists of 5 clinical projects and some preclinical approaches. Its lead project, mAb ch14.18 / CHO (APN311) is in phase III against neuroblastoma, nearing full recruitment. The immunocytokine hu14.18-IL2 (APN301) is in phase II (for certain neuroblastoma patients) and is also clinically tested against melanoma. Also in the clinical stage is a liposomal formulation of recombinant human superoxide dismutase (APN201) to prevent or treat skin damage due to radiation treatment in cancer. A further clinical project (APN01) was licensed to GSK in 2010. It is currently in phase II, recruiting patients with acute lung injury (ALI), and has considerable potential in other disease areas.

Company Profile


Management Team

CEO: Hans LoibnerCOO: Manfred SchusterCFO: Lukas Kadawy

Public Funding

aws Seed, Double Equity, ZiT, FFG, Wirtschaftskammer Österreich (Austrian Federal Economic Chamber): Not disclosed

Private Funding

Not disclosed

Technology

— Apeiron’s lead project targets an antigen (GD2) that is present on other cancers (e.g. sarcomas, small-cell lung cancer) as well. The first targeted line extension is melanoma.

Market

— Cancer remains an area with a very high unmet medical need. Neuroblastoma is an orphan indication that affects mainly infants. There is no sufficiently effica-cious therapy on the market.


— APN311 Neuroblastoma Phase III

— APN301 Neuroblastoma, melanoma

Phase II

— APN01 ALI Phase II

— APN201 Inflammatory skin conditions

Phase II

— APN401 Solid tumors Preclinical

— APN411 Solid tumors Under development

APEIRON Biologics AG

Campus-Vienna-Biocenter 51030 Vienna, Austria+43 1 865 65 [email protected]

Products

Hans Loibner, CEO Apeiron Biologics


APEPTICO is a privately held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases such as respiratory failure, pulmonary edema, acute lung injury, lung transplantation, ischemia reperfusion injury, and high-altitude edema. The peptide molecules correspond to validated, pharmaco- dynamic active structures and domains of well-known proteins and biopharmaceuticals. By concentrating on synthetically produced protein structures, APEPTICO avoids general risks associated with gene and cell technol-ogies. APEPTICO makes use of its technology platforms PEPBASE™ and PEPSCREEN™ to significantly reduce cost and to shorten time to market.

Company Profile


Management Team

CEO: Bernhard FischerCSO: Rudolf Lucas

Public Funding

aws PreSeed: € 100,000FFG: € 3.91M

Private Funding

€ 4.5M

Technology

— Respiratory failure, pulmonary edema, acute lung injury, lung transplantation, ischemia reperfusion injury, high-altitude edema

— We collect molecular, structural, biolog-ical, and medical data of well-character-ized proteins and biopharmaceuticals in our proprietary database, PEPBASE.

— Identification of a bioactive moiety is the first step of PEPSCREEN, our fast-track product development pathway.

— All molecules are protected by patents and fully owned by APEPTICO.

Market

— The therapeutic market for acute lung failure was worth $ 620M in 2011 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 1.3% to reach $ 681M by 2019.

— The therapeutic market data are for US, France, Germany, Italy, Spain, UK, and Japan.

— Total population of 750M.


— AP301-IH Respiratory failure Phase II

— AP301-IRI Lung transplantation Phase II

— AP301-PN Lung infection Phase II

APEPTICO Forschung und Entwicklung

Mariahilferstr. 136, Top 1.151150 Vienna, Austria+43 664 [email protected]

Products

APEPTICO’s lead compoud: AP301


BDS Pharma is a drug delivery company founded in June 2012. The company’s mission is to develop and commercialize a novel drug delivery platform that combines the use of conven-tional polymer drug delivery vehicles and approved drugs to be implanted directly within the Central Nervous System (CNS). The polymeric delivery devices can provide tailored release of appropriate doses of drugs for the given clinical population within the focal site in the impacted brain without causing systemic side effects.

Company Profile


Management Team

CEO: Bernd Pöcheim

Public Funding

aws Seed: € 500,000

Private Funding

Not disclosed

Technology

— Our lead product “Nicaplant” (patent pending) is a brain implant designed to prevent and treat cerebral vasospasm following aneurysmal subarachnoid hem-orrhage (aSAH) and other traumatic brain injuries. Cerebral vasospasm is a leading cause of permanent brain damage and death following aSAH.

— The manufacturing process is a com-mercially scalable melt extrusion process applying Nicardipine and a PLGA polymer matrix.

— The patent for Nicaplant has been filed for key markets including USA, Europe, Russia, South Africa, Brazil, Australia, Hong Kong, and Japan.

— BDS’s technology platform is designed to cover additional therapeutic areas including oncology, other neurodegen-erative disorders where site-specific delivery provides patient benefit, and gene therapy.

Market

— Treatment preventing cerebral vasos-pasm addresses a serious unmet med-ical need with a prevalence of approx. 10 patients / 100,000 people

— Expected to qualify as a rare disease to be eligible for an Orphan Drug status by European and US regulators (EMA, FDA)

— Our strategy to use conventional polymer drug delivery vehicles and approved drugs reduces development risk and cost, and increases speed to market.


— Nicaplant Treatment and prevention of cerebral vasospasm

Phase II

BDS Pharma GmbH

Marburger Kai 478010 Graz, Styria, Austria+43 664 356 038 9 [email protected]

Products

Illustration of Nicaplant application


Diagnosia was founded by a group of physicians and software devel-opers and is based in Vienna, Austria. The company is an independent European source for medical drug information provided through a sophisticated application that includes a broad variety of functions and allows fast access to relevant, synchronized professional information for doctors. In Austria, doctors don’t have relevant medical drug information when needed and no suitable user interface to interact with. Therefore, we provide up-to-date professional information by partnering with various governmental medical agencies all over Europe.

Company Profile


Management Team

CEO: Marco VitulaCTO: Christoph LupprichHead of Product: Lukas Zinnagl

Public Funding

aws Seed: € 150,000FFG: € 300,000

Private Funding

€ 235,000

Technology

— Our algorithm automatically converts package leaflets and professional infor-mation from pdf into digital format.

— Semantic analysis and machine learning of source files, paired with pdf-converting technology.

— The information is available in 14 lan-guages on mobile devices as well as on your personal computer.

— Entity extraction through machine learning approach

— Lean and efficient process to publish data

Market

— $ 1.08bn total US investments in digital health in 2012

— $ 320bn total health care system spending on medicines in 2011 (USA)

— $ 6.9bn projected mHealth revenue in Europe by 2017

— 73% more investments in digital health made in 2012 than 2011

— Digital health is a national game: each country has different technical implica-tions regarding its drug data structure.

Products

— Diagnosia Index: advanced cross- device drug information system available on Web, iPad, iPhone and Android. This state-of-the-art web application uses authorized public data sources and has plenty of add-on features.

Diagnosia Internetservices GmbH

Fillgradergasse 7/31060 Vienna, Austria+43 129 566 [email protected]

Diagnosia platform

— Diagnosia Check: Diagnosia Check is available as an iOS app that provides an up-to-date and evidence-based drug-drug and drug-food interaction tool for health care professionals.


Dutalys is a private Austrian antibody technology company, committed to developing superior treatments for complex and multifactorial diseases, including cancers and inflam-matory diseases. Dutalys has developed the DutaMab™ platform technology, to provide the only class of bispecific antibody molecules that retain all the advantages of state-of-the-art monospecific antibody therapeutics. The benefits of DutaMabs™ include high affinity against all classes of drug targets, convenient manufacturing fully equivalent to mono-specific antibody drugs, and outstanding stability.

Company Profile


Management Team

CSO, Cofounder: Roland BeckmannManaging Director: Mabel MakBusiness Adviser: Thomas von RüdenVP Research: Kristian Jensen

Public Funding

aws PreSeed: € 100,000aws Seed: € 1MOthers (FFG, ZIT, INiTS): € 655,000

Private Funding

Not disclosed

Technology

— While monospecific antibody drugs represent an important medical and commercial success, complex and multifactorial diseases such as cancers and inflammatory diseases are often not adequately treated by addressing a single drug target in patients. To address this unmet medical need, the pharmaceutical and biotech indus-tries have increasingly developed novel antibody formats, including bispecific antibodies directed against two drug targets.

— Previous bispecific antibody formats suffer from serious limitations, espe-cially in the areas of stability, manufac-turability, and discoverability.

— DutaMabs™ comprise two inde-pendent, non-overlapping paratopes within the natural CDR regions of a

fully human antibody, which can be independently selected and optimized in a robust and rapid manner to bind any two targets with high affinity and specificity.

— DutaMabs™ comprise only one normal fully human heavy-chain polypeptide and one normal fully human light-chain polypeptide and are extremely efficiently produced using all standard antibody manufacturing platforms.

— DutaMabs™ are based on fully human antibody scaffolds with world-record biophysical stability, and routinely achieve best-in-class thermal stability as well as excellent chemical and in vivo stabilities. Dutalys technologies are pro-tected by five independent patent fam-ilies. Dutalys’ freedom to operate has been independently verified.


— DutaMab™ Ultra-stable fully human bispecific IgG molecules

Preclinical

— DutaFab™ Ultra-stable fully human bispecific Fab fragments

Preclinical

— DutaLib™ Synthetic libraries of ultra-stable fully human bispecific antibodies

Preclinical

Dutalys GmbH

Muthgasse 11/2/31190 Vienna, Austria+43 1 [email protected]

Products

Market

— The global sales of therapeutic anti-bodies was USD 52 billion in 2010.

— The majority of growth in global drug sales in the next five years is expected to come from therapeutic antibodies.

DutaMab technology

— The pharmaceutical industry invested USD 18 billion in 2010 into R&D of biologics and is increasingly turning to external sources for innovation.


Eucodis Bioscience delivers high-performance enzyme solutions for highly specific applications in the biopharma, fine chemicals, and cosmetics industries. With a portfolio of over 50 enzymes, including innovative lipases, beta-lactamases, peroxidases, and other enzymes, Eucodis Bioscience has a proven track record of providing customized enzyme solutions. Eucodis specializes in setting up optimized bioprocesses for scale-up and manufacturing recombinant proteins under ISO 9001.

Company Profile


Management Team

CEO: Karl HüblerTechnical Director: Jan Modregger

Public Funding

aws Seed: € 500,000Others (FFG, WWFF, WAFF, ZIT, EU): € 1.25M

Private Funding

€ 8.87M

Technology

— Enzyme Engineering: Proprietary in vivo recombination, gene shuffling, and other technologies for protein and enzyme engineering.

— Fermentation Technologies: Most advanced expression systems using E. coli, P. pastoris, B. subtilis, and Asper-gillus oryzae for scalable production of enzymes and other proteins under ISO9001:2008 quality standards.

— Conjugation of Antibodies: A novel linker technology (CTAT technology) designed to covalently attach a recombinant anti-body or antibody fragment to a thera-peutic drug through a specific enzy-matic reaction. This directed conjugation method is site-specific and does not interfere with the antigen binding site.

— Applications: Antibody-drug conjugates (ADCs); labeling of recombinant pro-teins, antibodies, or antibody fragments.

Market

— Industrial enzymes for catalytical pro-cesses in the pharmaceutical, cos-metics, chemical, and food & feed industries.

— LacBusterTM targets a niche market with an annual sales volume of 20 mil-lion EUR.

— The ADC market is estimated to reach $ 5.8bn by 2016.

Products

— LacBusterTM : Innovative formulations of beta-lactamases for sterility testing and environmental monitoring in antibiotics production.

— Lipases: Panel of over 25 unique lipases carefully selected and engineered for applications in the chemical, pharma-ceutical and food & feed industries. The enzymes show superior activity in mul-tiple applications, such as the production

Eucodis Bioscience GmbH

Viehmarktgasse 2a/2OG1030 Vienna, Austria+43 1 8900 804 [email protected]

Eucodis product

of nutritionally valuable fats and oils, emol-lient ester synthesis and API production

— Peroxidases, Phospholipases D: Libraries for industrial applications

— Services: Solutions for Biocatalysis and protein production including bioprocess development, enzyme identification, pro-tein engineering, up to industrial-scale manufacturing of enzymes and proteins as CMO.


EveliQure Biotechnologies aims to develop efficacious vaccines to reduce the high burden of diarrheal diseases among travelers and young children living in resource-poor countries. It is widely accepted that prophylactic vaccination would be the most effective way to address this high unmet medical need; yet, no vaccines are currently available.

Company Profile


Management Team

MD: Zoltán DobaiCSO: Tamás Henics

Public Funding


Private Funding

€ 30,000

Technology

— EveliQure has developed a novel vac-cine technology platform based on a live attenuated Shigella strain. The plat-form is amenable for the heterologous expression of diarrheal antigens and can therefore provide protective immunity against multiple pathogens.

— EveliQure’s first vaccine candidate, SHIGETECTM is intended to be devel-oped as a drinkable (oral) vaccine. It contains the attenuated Shigella vaccine strain that expresses ETEC antigens known to induce protective immunity when expressed in appropriate forms.

— EveliQure filed a patent to protect the technology platform and the first vac-cine candidate.

Market

— The market demand for ShigETECTM comes from three target groups: trav-elers from industrialized countries to developing countries; military per-sonnel (US & NATO, etc.) stationed in developing countries; NGOs and gov-ernments of the developing countries where Shigella and ETEC infections are endemic.

— Global demand is estimated to reach approximately 100 million doses per year, with revenues peaking around $ 600M 12 years after launch.

— No vaccines currently available.


— EveliQure Vaccine Technology Platform

Diarrheal diseases Preclinical

— SHIGETEC vaccine Shigella, ETEC Preclinical

EveliQure Biotechnologies GmbH

Helmut-Qualtinger-Gasse 21030 Vienna, Austria+43 680 243 447 [email protected]

Products

EveliQure technology


Evercyte is a provider of relevant preclinical model systems that will enable the acceleration of drug discovery and development by reducing development time and cost. These cellular model systems are based on primary cells that are immor-talized either without altering key functional characteristics or by using adult stem cells and urine-derived, induced pluripotent stem cells.

Company Profile


Management Team

CEO, co-founder: Otto KanzlerCSO, co-founder: Johannes GrillariCo-founder: Regina Grillari

Public Funding


Private Funding

Not disclosed

Technology

— Preclinical model systems, drug research and development, screening, toxicology, primary-like immortalized cell lines, adult stem cells, induced pluripo-tent stem cells, differentiation of cells, contract research, urine-derived cells

— Immortalization of human cells using tel-omerase and/or viral oncogenes

— Production of induced pluripotent stem cells from human-urine-derived cells. The non-invasive nature of this tech-nology allows easy donor recruitment

— Pharmacocellomics: production of panels of immortalized cell lines of dif-ferent donors and/or different tissues for better estimating effects of substances on the general population

Market

— The global cell-based assay’s market will reach $ 1.5bn in 2017, according to a new report by Global Industry Analysts, Inc.

— Industry: Biotech – preclinical model systems, toxicology model systems for pharma, chemical, and cosmetic industry

— Clients: Companies from pharmaceu-tical and biotechnological industries, chemical and cosmetic industries, environmental toxicology, CROs

Products

— Immortalized cell lines: Evercyte offers immortalized primary human cells and/or cell panels of different donors and/or different tissues for preclinical target and drug discovery, drug development, and quality control during drug manufacturing.

Evercyte GmbH

Muthgasse 181190 Vienna, Austria+43 699 18162222 (scientific issues)+43 664 4227861 (business issues)[email protected]

HUVEC TERT2 endothelial cells

— Customer-tailored cell lines: Evercyte offers services for the development of (immortalized) customer-tailored cells and cell-based assays.

— Cell-based assays and research & development


F-star develops bispecific antibody products to improve the treat-ment of serious diseases. F-star is the only biopharmaceu-tical company creating bispecific antibodies by modifying the constant region of an antibody. Our Modular Antibody Technology offers unprecedented ease in the development and manufacturing of bispecific antibody products.

Company Profile


Management Team

CEO: John HaurumCOO: Jane DancerVP Discovery: Mihriban TunaVP Biological Products: Haijun SunExecutive Program Director: Kate Seaber

Public Funding

aws: € 1.5MFFG: € 1.5MINITS: € 60,000

Private Funding

€ 30M

Technology

— Our robust Modular Antibody Tech-nology enables the rapid design and creation of large panels of bispecific antibodies. These “2-in-1” drugs offer the potential for powerful synergistic benefits not achievable by co-adminis-tration of individual drugs.

— We first modify the constant region of an antibody to bind to a therapeutic target of interest (an “Fcab™” ); then we utilize our modular recombination approach to create genuine bispe-cific monoclonal antibodies that bind two different antigens at the same time (“mAb2™”).

— The simple “mix-and-match” capability of F-star’s highly efficient discovery engine creates virtually limitless bispe-cific product opportunities.

— F-star’s IP portfolio provides exclusivity around its Fcab™ and mAb2™ technol-ogies and their applications.

Market

— Total biologics sales expected to grow by 45% between 2010 and 2016 from $ 130bn to $ 192bn

— Top 3 selling global pharmaceuticals projected to be biologics in 2016

— Targeted biologics represent the most significant market segment within bio-logics with > 50% of total biologics revenue today and double-digit annual growth over the past decade


— H561-4 Solid tumors Preclinical

F-star GmbH

Schwarzenbergplatz 71030 Vienna, Austria+44 122 349 740 [email protected]

Products

CEO: John Haurum


GAT Microencapsulation is an agrochemical company specializing in the develop-ment, registration, and manufacture of advanced plant protection products. GAT has developed innovative and cost-effective technologies for the formulation of agrochem-icals, most notably microencapsulation. The company’s intellectual property in these technologies is based on a complex combination of international patents.

Company Profile


Management Team

CEO: Barbara GimenoCTO: Miguel GimenoCFO: Wilfried Wiesinger

Public Funding

aws Seed: Not disclosedaws others: Not disclosed

Private Funding

100%

Technology/Innovation

— Formulation/regulatory development — PCT patents on CS and OD technology — Global licensing, distribution, and service

agreement with FMC Corporation USA

Market

— Global market size $ 50bn — European agrochemical market $ 11.5bn

in 2012 — Annual growth rate 5.4% p.a. till 2018

Services Description of Service

— Service 1 Contract research under GLP

— Service 2 Manufacturing

— Service 3 Regulatory services

GAT Microencapsulation AG

Gewerbezone 12490 Ebenfurth, Lower Austria, Austria+43 262 453 922 [email protected]

Services

GAT Headquarters


Haplogen Haplogen’s mission is to improve human health by combating infectious disease. Employing proprietary genetics technology to identify host factors, Haplogen is building a pipeline of therapeutic programs in the area of viral diseases. Its most advanced program develops antiviral substances against rhinovirus.

Company Profile


Management Team

CEO: Georg CasariHead of Science: Tilmann Bürckstümmer

Public Funding

aws Seed: Not disclosedOthers (FFG, ZIT): Not disclosed

Private Funding

Not disclosed

Technology

— Antiviral therapies are constantly chal-lenged by rapidly emerging resistant strains.

— Targeting a host factor places a far higher barrier for resistance and can enable the development of more pow-erful drugs.

— Haplogen’s technology delivered a pipe-line of first-in-class host factor targets that are used to develop antiviral drug candidates.

— Haplogen holds exclusive licenses and has applied for several proprietary anti-viral patents.

Market

— Most viral diseases have no therapy available, and patients receive sympto-matic treatments.

— Rhinovirus infects adults on average four times a year with no therapy avail-able. Globally, this represents a multibil-lion-dollar market.

— Several acute viral diseases have no therapy available and each represents a potential billion-dollar market

— Haplogen develops therapeutic agents up to clinical candidates. We then outli-cense or develop them in partnerships with biotechnology and pharmaceutical companies.


— PT1 ICD B34.8 Common cold Preclinical phase

— Human knock out cell lines Research tools Marketed

Haplogen GmbH

Campus Vienna Biocenter VBC51030 Vienna, Austria+43 1 916 552 [email protected]

Products

Haplogen technology


Innovacell Biotechnologie is a privately held biotechnology company based in Inns-bruck, Austria, with a focus on incontinence. The company focuses on the clinical development and commercialization of autologous (i.e. patient’s own cells), minimally invasive cell therapies. INNOVACELL’s personalized products are potentially curative one-off treatments, which re-establish functionality of sphincter muscles in patients, e.g. with stress urinary incontinence (SUI) or fecal incontinence (FI).

Company Profile


Management Team

CEO: Ekkehart SeinhuberCSO: Rainer Marksteiner

Public Funding

aws Seed: € 400,000aws TFP guarantees: € 2.7M

Private Funding

Not disclosed

Technology

— ICES13 is the autologous tissue engi-neering product for the treatment of patients suffering from stress urinary incontinence (SUI).

— Innovacell has completed recruitment for the multicenter Phase III clinical trial of ICES13 in Europe. Marketing authori-zation in the EU is expected to be avail-able by the end of 2014.

— ICEF15® is the autologous tissue engineering product for the treat-ment of patients suffering from fecal incontinence.

— Following successful proof-of-con-cept studies for ICEF15®, Innovacell will start a multicenter Phase IIb trial in Q3/2013. Regulatory approval in the EU is expected to be available in 2018.

Market

— ICES13® addresses a market of approx-imately 23 million patients suffering from SUI in the top seven global markets including 2.2 million new patients every year, for which ICES13® could be the treatment of first choice.

— Top 7 global markets for fecal inconti-nence are estimated to contain 2.5 mil-lion patients in need of therapy.


— ICES13 Stress urinary incontinence Phase III

— ICEF15 Fecal incontinence Phase IIb

Innovacell Biotechnologie AG

Mitterweg 246020 Innsbruck, Austria+43 512 573 [email protected]

Products

Innovacell technology


INOXIA Lifesciences is an innovative, newly founded biotech company that specializes in the field of drug development with human peroxidase as the main target. Peroxidases are innate immune system enzymes, which are responsible for chronic inflammatory and neurodegenerative diseases. Selective potential inhibitors form the basis for new medication to be used for the treatment of asthma, COPD, endometriosis, and bowel diseases such as ulcerative colitis to mention a few. The company is developing small molecule candidates for entry into clinical trials.

Company Profile


Management Team

CEO: Andreas KubinCSO: Martina ZederbauerCFO: Georg Jessner

Public Funding

aws PreSeed: € 200,000Others (FFG, ZIT): € 200,000

Private Funding

€ 300,000

Technology

— Local accumulation of eosinophils causes chronic inflammatory processes through the release of eosinophil perox-idase (EPO).

— INOXIA’s innovation is the develop-ment of selective inhibitors against the enzyme EPO, in order to prevent and reduce the progress of chronic inflam-mation of several diseases. There are initial promising results regarding the efficacy of EPO inhibitors in asthma animal models.

— WO2011091461A1: The patents com-prise possible derivatives of the lead substance AW/EPO/003 for several indications.

Market

— The global market for asthma medica-tion covers $ 33bn (annual growth rate 4.4 %) and for ulcerative colitis $ 1.7bn (growth rate 8.5%).

— Typical asthma pharmaceuticals are corticosteroids and bronchodilators. No inhibitor against eosinophil peroxidase for the treatment of inflammatory pro-cess is currently on the market.

— Blockbuster scenario for asthma opens up promising perspectives for investors.


— AW/EPO/003 Asthma Preclinical

— AW/EPO/PD01 Colitis Preclinical

— AW/EPO/XXX Endometriosis Under development

INOXIA Lifesciences GmbH

Erlgasse 481120 Vienna, Austria+43 1 810 536 [email protected]

Products

Target: EPO active site + inhibitor


Inte:Ligand is a research-based software development and consulting company that helps clients and partners in the life sciences industry to prioritize and de-risk novel bio-active molecules for development.

Company Profile


Management Team

CEO: Sharon D. BryantCSO: Gerhard Wolber

Public Funding

aws Seed: Not disclosedOthers (FFG, EC FP7): Not disclosed


— Inte:Ligand’s software products support scientists in the life sciences industry to select the best-suited candidates for biological evaluation and develop-ment. With LigandScout, the most user-friendly software for advanced phar-macophore modeling, and by using accurate and rapid in silico screening, the most promising molecules can be selected and optimized. With the Phar-macophoreDB, compounds can be de-risked for further development as drug candidates.

Market

— global life sciences market — pharma, biotech, agro, nutraceutical,

and cosmetic industry


— LigandScout 3.0 Fully integrated platform for accurate virtual screening of candidates based on 3D chemical feature pharmacophore models

— Contract Research 3D Pharmacophore DevelopmentVirtual ScreeningGeneration of Customized Virtual LibrariesLead Structure Optimization

Inte:Ligand Software-Entwicklungs- und Consulting GmbH

2344 Maria Enzersdorf, Lower Austria, AustriaClemens Maria Hofbauer-Gasse 6+43 699 150 752 [email protected]

Services

Sharon D. Bryant; Inte:Ligand CEO


Lexogen is an ambitious biotech start-up based in Vienna, Austria,developing unique proprietary expression profiling tech-nologies. Founded in 2007, Lexogen currently has 26 employees and is funded by both private capital and public funds, in particular by Austrian Research Promotion Agency FFG, Austria Wirtschaftsservice aws, INiTS, and Wirtschaftsagentur Wien.

Company Profile


Management Team

CEO: Alexander SeitzCSO: Torsten Reda

Public Funding

aws PreSeed: € 50,000aws Seed: € 1MOthers (FFG): € 3.85M


— Lexogen specializes in the development of novel RNA sequencing library prepa-ration methods. The main assets are a series of RNA segregation systems to obtain different RNA fractions of interest. The subsequent transformations into libraries are compatible with any mas-sive parallel sequencing technologies.

— Lexogen has a proprietary technology portfolio that is protected by a growing number of patent applications. Currently, 9 patent applications have been made in the areas of molecular biology, process and nanotechnology, and bioinformatics.

Market

— The world Next Generation Sequencing market includes instruments, consuma-bles, and related services and was esti-mated in 2012 as $ 1bn (CAGR 17%). USA has the biggest share of the market, 51.8% (CAGR 22.7%), Europe has 31.1% (CAGR 21.1%), and Asia has 14% (CAGR 26.8%).

— RNA sequencing constitutes 25% of the overall NGS market. The key NGS platforms are provided by Illumina (San Diego, CA, United States of America) and Life Technologies (Carlsbad, CA, United States of America).

The Lexogen Service

Lexogen GmbH

Campus Vienna Biocenter 51030 Vienna, Austria+43 1 345 [email protected]

Product Description of Product

— SENSE SENSE is a complete strand-specific mRNA-Seq library preparation kit for accurate gene expression profiling, transcriptome sequencing, and discovery, assuring the precise quantification of antisense transcripts and overlapping genes.

— SPLIT The SPLIT RNA Extraction kit enables a fast and highly efficient ex-traction of RNA that is free of genomic DNA contamination. The RNA can be recovered as total RNA or split into a large and a small RNA fraction, facilitating the analysis of, for example, mRNA and miRNA from the same sample.

— SQUARE (service)

SQUARE enables hypothesis-free identification and quantification of all known and unknown full-length transcripts. The technology selectively amplifies transcript variants – including splice variants – in a scalable number of so-called matrix fields. Following NGS, transcript hypothe-ses can be generated reliably for the reduced variant complexity within the matrix fields. Together with nucleotide-level start- and end-site tagging, SQUARE enables the detection of known and the discovery of novel transcript variants. Differential gene expression analyses can be performed on the level of transcript variants, providing investigators with more significant information about transcriptomic differences.

Products


Marinomed is focused on the development of innovative therapies against respiratory diseases (such as common cold and influenza) based on an innovative anti-viral respiratory tech-nology platform called Mavirex. Safety and effectiveness of the Mavirex platform have been proven in three clinical trials in adults and children and by its marketed anti-viral OTC common cold and influenza portfolio. Furthermore, Marinomed has a pipeline of proprietary compounds in allergy and autoimmune diseases that are in development.

Company Profile


Management Team

CEO: Andreas GrassauerCSO: Eva Prieschl-GrassauerHead Development: Angelika BodenteichHead Finance: Helmut BaranyovszkHead Business Development: Johanna UhlmannHead Research: Martina Kurz

Public Funding

Not disclosed

Private Funding

Not disclosed

Technology

— Mavirex is a powerful platform for the development of products against vira infections such as common cold and influenza. Four products have been approved for marketing in the EU and abroad. Additional Mavirex-based prod-ucts will hit the market within the next two years.

— A strong product pipeline boasts a novel immunomodulator MAM-08.101, the anti-allergic MAM-06.301, and a novel class of anti-infectives.

Market

— The world market for cold, cough, and sore throat remedies is projected to exceed $ 22.2bn by the year 2015. This is primarily driven by a rise in the pop-ulation suffering from cold, cough, and sore throat symptoms, and the introduc-tion of effective medications.

— Market proof of concept: Marinomed’s lead product, an innovative anti-viral common cold nasal spray containing Carragelose®, a polymer of the Mavirex platform, is outlicensed to Boehringer Ingelheim, covering 55 countries in Europe, Russia and CIS, South America, parts of Asia, and Australia. 29 countries are licensed to local partners.

— The product is already marketed in 13 countries worldwide.


— Anti-viral OTC Portfolio Common cold, influenza Marketed

Marinomed Biotechnologie GmbH

Veterinärplatz 11210 Vienna, Austria+43 1 250 774 [email protected]

Products

Coldamaris Product


Mucokinetica is an epithelial biology drug discovery and development company. Our lead product is an orphan drug treatment for cystic fibrosis lung disease. By reducing excessive sodium absorption in the airways, we aim to deliver disease-mod-ifying, long-duration relief from the adverse effects of the major driver of CF chronic lung disease.

Company Profile

Founded: In foundationEmployees: 2

Management Team

CEO/CSO, co-founder: Rod HallCMO, co-founder: Peter Cole

Public Funding


Private Funding

€ 20,000

Technology

— MKA 104 is a small-molecule drug re-purposing opportunity with reduced risks of failure in development compared to NCEs.

— MKA 104 is a solution to the problem of excessive sodium absorption in the air-ways with disease-modifying potential for CF.

— MKA 104, through inhalation, inhibits activation of sodium channel proteins in the airway surface epithelium and pro-vides long-duration reduction of and relief from the excess sodium absorption that is the major driver for chronic lung disease in CF.

— IP Status: MKA 104 method of use pat-ents; MKA 104 designated for orphan drug development in EU

Market

— 80,000 CF patients worldwide — CF patient number annual growth 3 to 6%

— MKA 104 targets all CF patients, all CF genotypes

— CF major markets are EU and US (CF is extremely rare in Japan)

— CF therapeutic market value $ 1.1bn (Global Data Report 2010); estimated to grow to $ 2.1bn by 2017

— Further market opportunities: COPD; Non-CF bronchiectasis


— MKA 104 Cystic fibrosis Under development

— MKA 109 Women’s health – vaginal dryness Under development

Mucokinetica

Schiffmühlenstrasse 47 / 3301220 Vienna, Austria +43 669 182 693 [email protected] www.mucokinetica.com

Products

Ion channel pharmacology studied in pig airway organ explants


Origimm is a young, ambitious Austrian biotech company striving to become a market leader in protective antigen discovery. Using its proprietary ProVaDis® technology platform, Origimm overcomes the challenges in vaccine and immune therapy development with early focus on protective efficacy of antigens in the context of human disease. This translates into a rapid selection of best, most-protective candidates with a significantly improved success in clinical trials. Origimm is developing the first therapeutic vaccine for treatment of acne vulgaris; the disease with enormous market potential, afflicting 85% of teenagers and more than 10% of adults.

Company Profile

Founded: 2012Legal Form: e.U.Employees: 3

Management Team

CEO: Sanja SelakCSO: Sanja SelakCFO: Thomas Fischer

Public Funding

aws PreSeed: € 200,000ZIT: € 420,000INITS: € 30,000+

Private Funding

Series A/2014

Technology

— Currently 85% of all vaccine candidates that enter Phase I clinical trial, fail to be approved for the market. More than 1/3 of all the clinical failures can be traced back to the suboptimal selection of vac-cine antigens. The main challenge is predicting protective efficacy of antigen candidates, because current methods do not incorporate tests for protective efficacy during early stages of antigen screening.

— ProVaDis® (Protection-based Vac-cine Discovery) technology overcomes these challenges by incorporating pro-tective efficacy testing in the very early stage of antigen screening, ensuring the selection of the most protective vaccine antigens.

Market

— The global vaccine market is expected to increase by more than 100% from $ 24bn in 2009 to $ 56bn in 2016. Vaccines are becoming increasingly important as revenue generators within the portfolios of the key pharma players.

— The global acne treatment market is estimated to reach revenues of $ 3.1bn by 2017 at a Compound Annual Growth Rate (CAGR) of 0.7% at ~$ 3bn.


— Therapeutic vaccine Acne vulgaris Preclinical

Origimm e.U.

Leberstrasse 201110 Vienna, Austria+43 676 448 [email protected]

Products

Sanja Selak, CEO Origimm


Panoptes Pharma “Vision is our Mission”: Panoptes develops small-mole-cule-based therapies for autoimmune- and viral-caused indications in ophthalmology with high unmet medical needs. Panoptes’ clinical candidate PP-001 is currently in preclinical development for autoimmune uveitis and adeno-viral conjunctivitis. PP-001 will provide much-needed treat-ment options that are more efficacious and more tolerable and therefore provide a better quality of life for patients with these eye diseases.

Company Profile


Management Team

CEO: Franz ObermayrCOO: Stefan Sperl

Public Funding

aws Seed: € 1M

Technology

— PP-001 is a highly specific nanomolar inhibitor of an essential enzyme of the de novo pyrimidine pathway, inhibiting the expression of IFN- and IL-17, two hallmark cytokines responsible for auto-immune uveitis.

— PP-001 was shown to be efficacious in 2 different animal models for uveitis.

— PP-001 reduces the host cell pyrimidine pool, inhibiting the replication of ade-novirus serotypes that cause the highly contagious viral form of conjunctivitis.

— Unique physicochemical properties of PP-001 allow systemic and local administration.

— Panoptes owns about 60 patents and patent applications worldwide, pro-tecting PP-001 and its use.

Market

— Addressable market for both indications is > $ 700M each.

— For conjunctivitis, no anti-viral drug is on the market.

— Uveitis is currently treated with corticos-teroids with severe adverse effects.

— PP-001 has the potential to be devel-oped for further indications like dry-eye syndrome, psoriasis, different viral infec-tions, etc.


— PP-001 Uveitis Preclinical

— PP-001 Viral conjunctivitis Preclinical

Panoptes Pharma Ges.m.b.H.

Parkring 101010 Vienna, Austria+43 664 [email protected]

Products

Franz Obermayr, CEO, & Stefan Sperl, COO


PDC Biotech is a biotechnology company developing novel compounds for the treatment of preterm labor and primary dysmenorrhea, two areas of significant unmet medical need and large market potential. Excessive uterine contractility in both conditions is mediated by prostaglandin F2 (PGF2 ). At the core of the company is a unique, proprietary series of PGF2 receptor antagonists.

Company Profile


Management Team

Managing Director: Roman Goetz

Public Funding

aws Seed: € 1MZIT: € 516,654

Private Funding

€ 6.23M

Technology

— Preterm labor is defined as regular con-tractions associated with cervical changes occurring before 37 weeks of gestation.

— Primary dysmenorrhea is characterized by cramping pelvic pain caused by frequent and prolonged uterine contractions that decrease blood flow to the myometrium.

— PDC’s lead compound, PDC31 is a synthetic octapeptide that is a potent, non-competitive, selective antagonist of the PGF2 receptor.

— In vitro models have shown that PDC31 inhibits spontaneous and PGF2 -induced uterine contractions; in vivo animal models have shown that PDC31 significantly pro-longs pregnancy.

— In a first-in-human study, administration of PDC31 was associated with a reduction in intrauterine pressure as well as with a dose-dependent relief of dysmenorrhea pain.

— PDC Biotech has licensed exclusive worldwide rights to a family of FP receptor antagonists from Theratechnologies Inc. (www.theratech.com).

Market

— Preterm birth is a major public health care issue; approximately one in ten babies in Europe is born prematurely.

— In the US, the reported rates of pre-term births are among the highest in the world. In 2008, nearly 500,000 infants (12.3%) were born preterm.

— Annual societal economic burden asso-ciated with preterm birth in the US was estimated at $ 26.2bn, $ 52,000 per infant born preterm.

— Health care costs are about 10 times greater for preterm than for term infants.

— Primary dysmenorrhea is a disabling condition found in approx. 10–15 % of women of childbearing age; it is esti-mated to account for 600M lost work hours ($ 2bn in lost productivity) annu-ally in the US alone.


— PDC31 Preterm labor Phase I completed

— PDC31/PDC41 Primary dysmenorrhea Phase I completed

PDC Biotech GmbH

Kärntner Ring 10/121010 Vienna, Austria+43 189 000 771 [email protected]

Products

Novel compounds for the treatment of preterm labor and primary dysmenorrhea


Procomcure Biotech The need addressed by Procomcure is the dearth of novel antibacterial agents. The company has now identified a new class of antimicrobial compounds with activity against clinically important antibiotic-resistant bacterial infections, and has technology to address modes of antibiotic action and development of resistance. To advance drug develop-ment, the company pursues a hybrid business model of drug discovery and commercialization of its state-of-the-art technology platform.

Company Profile


Management Team

CEO: Kamil ÖnderCSO: Kamil Önder

Public Funding

aws PreSeed: € 100,000aws Seed: € 1MOthers (Tech2B, EU, FFG): € 500,000

Technology

— The growth of life-threatening, anti-biotic-resistant pathogens highlights the urgent need for a new classes of antibiotics.

— Procomcure has promising lead-com-pounds of a new class of antibacte-rial agents with activity against methi-cillin-resistant Staphylococcus aureus (MRSA), and the company has propri-etary tools for analysis of anti-bacterial modes of action. These tools originate from Procomcure’s patentable tech-nology platform on protein-protein inter-actions, including a MRSA/MSSA strain collection composed of >3000 strains each manipulated for a single S. aureus gene in a constitutive or inducible fashion, which allows Mode of Action in a systematic and genome-wide manner.

Market

— While the global antibiotics market gen-erated $ 42bn in 2009, representing 46% of anti-infective agent sales and 5% of the global pharmaceutical market, the smaller market of severe (noso-comial) infections caused by drug-re-sistant organisms is more tangible, offers higher drug prices and higher growth, and is therefore attractive. The global market of broad-spectrum anti-biotics showed annual growth rates of 3.4–5% between 2005 and 2009. Our focus, the methicillin-resistant Staphylo-coccus aureus (MRSA) market, stood at $ 1.45bn in 2006, which then grew at a compound annual growth rate of 12.9% to reach $ 2.66bn in 2011. The forecasts are that the market will grow to reach $ 3.47bn by 2019.


— PCC293 MRSA Preclinical

— PCC560 MRSA Preclinical

Procomcure Biotech GmbH

Magnesitstrasse 13500 Krems, Lower Austria, Austria+43 664 161 077 [email protected]

Products

Procomcure technology


ProFem is a company that develops new medicines for gyneco-logical diseases. The aim is to address hitherto unmet medical needs in neglected therapeutic areas with high market potential. The present focus of interest is related to a disease pattern associated with biofilm growth, which up to now represents an unsolved medical problem in several extremely relevant indications. The lead product is the anti-fungal medicine Prof-001, which is now in clinical phase I.

Company Profile

Founded: 2012Legal Form: GmbHEmployees: 1.5

Management Team

CEO: Marion NoeAdvisor: Christian Noe Advisor: Peter Swetly

Public Funding

aws PreSeed: € 195,000Others (ZIT, Inits): € 202,000

Private Funding

€ 500,000

Technology

— 5% of all women suffer from recurrent vulvovaginal infections caused by can-dida yeasts (RVVC), which up to now cannot successfully be treated.

— Making use of a specific drug repur-posing approach, Profem addresses for the first time adhesion molecules, which play a crucial role in infection as tar-gets for the treatment of infectious dis-eases. Preliminary tests in humans were extremely successful.

— A first patent covering the general ther-apeutic principle has been filed and has been granted in the USA recently. Fol-low-up patents covering drug formula-tion and other drug combinations are in preparation.

Market

— The new possibility to treat RVVC is rele-vant for about 200 to 300 million women worldwide. In figures, this means a market potential of more than $ 1bn.

— The global antifungal market is worth more than $ 11bn.

— The estimated market share of vaginal fungal infections is $ 2.5–3bn.

— Related diseases like chronic bacterial infections and chronic/recurrent infec-tions of the lower urinary tract also affect more than 10% of all women worldwide.


— Candiplus (Prof-001) (Recurrent) vulvovaginal candidiasis

Phase I

— Candiplus oral (Prof-002) Oropharyngeal candidiasis Related to development of Candiplus

— Prof-003 Urinary urge incontinence Preclinical

Profem GmbH

Riglergasse 4/I1180 Vienna, Austria+43 676 [email protected]

Products

Marion Noe, CEO of Profem


RECARDIO is an Austrian-based life sciences company founded in 2011. Its focus is on regenerative therapeutic modalities for the treatment of cardiovascular diseases. After establishing proof-of-principle in vivo, it is developing multiple therapeutic leads and is entering the clinical development as the future regenerative medication for patients with various cardiovas-cular diseases, with the potential of improving their cardiac function, quality of life, and likelihood of survival.

Company Profile


Management Team

CEO: Roman SchenkCSO: Thomas SchöndorfCBD: Harald Kattnig

Public Funding

aws Seed: € 1MFFG: € 250,000

Private Funding

€ 500,000

Technology

— RECARDIO’s first non-invasive and inno-vative therapeutic concept is the combi-nation of G-CSF with the recently avail-able DPPIV inhibitors, leading to a sig-nificantly increased regenerative effect in the diseased cardiac tissue. Targeting two established modes of action ame-liorates the effects of cardiac remode-ling with the intended long-term benefit of reducing morbidity and increasing survival.

— Additional key issues: safe and easy administration, preclinical development completed, key patents issued.

Market

— Cardiovascular diseases are the number one cause of death in Western coun-tries, claiming approximately 1.1 million lives in the US. Myocardial infarction (MI) causes the majority of cardiovascular deaths with an incidence of 600 per 100,000. Improvements in heart function with existing therapy methods are rather modest. Congestive heart failure (CHF), which develops after infarction, remains a major cause of morbidity and death and affects 4.8 million individuals in the US, with 400,000 new cases each year. Up to 74% of MI lead to CHF, which has a 5-year mortality of more than 60% in the affected population and an average survival rate of less than 1.7 years after diagnosis.


— REC 001 AMI Phase IIb

— REC 002 CHF Preclinical

— REC 003 PAD Preclinical

RECARDIO GmbH

Lakeside B07b9020 Klagenfurt, Carinthia, Austria+43 463 210 [email protected]

Products

Recardio technology


roombiotic is a biotechnological company developing decontamination technologies based on airborne antimicrobial substances. These small molecules belong to secondary metabolites, which are involved in the signal transduction of microorgan-isms. The company specializes in the identification of novel antimicrobial substances from natural occurring microbial antagonists. The main focus is a residue-free decontamina-tion of complex surfaces and microstructures with biogenic substances.

Company Profile

To be founded: 2014Legal Form: TBDEmployees: 3

Management Team

CRO: Stefan Liebminger (founder)CRO: Josef Ortner (Business Mentor)CRO: Gabriele Berg (Scientific Mentor)

Public Funding

aws PreSeed: € 200,000Science Park Graz: € 26,000

Technology

— Identification and synthesis of new vola-tile organic compounds from plant- derived beneficial microorganisms

— The pipeline includes several small molecules that allow for a residue-free decontamination of hard-to-reach areas.

— The process of the microbiological sta-bilization also includes promoting the growth of beneficial microbes, which outcompete pathogens.

Market

— The primary cause of food loss is due to food spoilage after distribution (FAO). In the United States alone, this repre-sents an economic loss of $ 1bn per annum.

— Markets targeted by roombiotic are food production (bakeries, dairy, meat processing).

— Additional markets are pharmaceutical industries and medical facilities.

Products Description of Service

— Analysis Analysis of the present microbiome and identification of critical areas and microbiological contaminations

— Development Development of biological strategies to control and reduce contamination for specific production processes

— Implementation Implementation of a contamination control system based on effective organic agents to improve product quality and shelf life

roombiotic

Petersgasse 12/18010 Graz, Styria, Austria+43 316 873 881 [email protected]://sciencepark.at/unsere-firmen/448/roombiotic

Services

Volatile antimicrobials enable the decontamination of microstructures (gray), which form shielding niches for microbes (green)


Savira is dedicated to the development of next-generation anti-influenza therapeutics. Savira employs rational, struc-ture-based design of small-molecule drugs targeting the influenza virus polymerase based on the inhibition of two distinct protein domains. In May 2012, Savira signed a collaboration and license agreement with Roche for its complete polymerase inhibitor program.

Company Profile


Management Team

CEO: Oliver SzolarCSO: Helmut BuschmannCFO: Andreas Hauer

Public Funding

aws Seed: € 1M Others (FFG, ZIT): € > 1MEU-FP7– FLUPHARM development partners: € 4M

Private Funding

€ > 2.9M

Technology

— Through a unique mechanism called ‘cap-snatching,’ the influenza virus forces the infected cell to produce viral proteins, eventually forming new infec-tious viral particles. Research by the EMBL identified the molecular architec-ture of both domains of the influenza polymerase crucial for this mechanism, the cap-binding domain and the endo-nuclease-active site.

— Structure-based medicinal chemistry programs have provided highly selec-tive ligands, with binding affinities being increased by several orders of magni-tude and improved in vitro inhibition of influenza virus replication in infected cells.

— In vivo antiviral proof of concept in mice with lethal influenza virus infection was demonstrated for both, cap-binding and endonuclease inhibitors.

— The most promising scaffold fami-lies have been protected worldwide by patent applications. Preclinical develop-ment is expected to start in 2014.

Market

— Influenza is an infectious viral respiratory disease and a major public health con-cern. Vaccines are considered to be an efficient prophylactic measure, but only a small part of the population is being vac-cinated, and the production of vaccines against new subtypes may take several months. Thus, antivirals are an indispen-sible treatment option.

— The influenza therapeutic market is expected to grow steadily from $ 4bn in 2009 to over $ 10bn in 2019, over-taking vaccines. Currently, it is made up of two main groups, with neuraminidase inhibitors (Tamiflu, Relenza, Rapiacta, Inavir) dominating over M2-ion channel inhibitors.

— Development of viral resistance is a recurring concern—most recently with the global emergence of Tamiflu-resistant strains in the 2007/2008 season. As a consequence, there is significant poten-tial in the market for novel, efficacious, and selective therapeutics less prone to the development of viral resistance.

Savira pharmaceuticals GmbH

Veterinärplatz 1, Building IA1210 Vienna, Austria+43 1 25077 [email protected]

Savira Management: Oliver Szolar, Andreas Hauer and Helmut H. Buschmann

Products

— Savira’s polymerase inhibitors are ide-ally placed to tap this market opportu-nity: binding to defined sites within the viral polymerase allows direct inhibition of viral RNA genome transcription; the structurally highly conserved sites are less prone to resistance development as they interact with host proteins, and minor structural changes have been shown to render the virus less virulent.

— The collaboration and license agreement with Roche provides Savira upfront pay-ments, R&D support, and milestone payments up to € 240M as well as roy-alties. Savira’s compounds will have the best possible access to the market through Roche’s very strong foothold in the field.


SeaLife Pharma is an innovative marine biotechnology company dedicated to the discovery and development of novel bioactive compounds. SeaLife Pharma’s R&D is focused on devel-oping new and commercially valuable products derived from marine microbiology. By combining a robust screening process with purification chemistry and compound eluci-dation, the company is well positioned to rapidly discover new pharmaceuticals and natural products for consumer health care.

Company Profile


Management Team

CEO: Alexander Pretsch CSO: Christoph Wiesner CFO: Andreas Krems

Public Funding

aws PreSeed: € 100,000Others: € 2.3M

Private Funding

€ 2M

Technology

— The core aim of the company is the dis-covery of anti-infective compounds tar-geting bacterial, fungal, and viral infec-tions with a focus on finding new anti-biotics to treat Gram-positive infections such as MRSA and VRE.

— In addition to the therapy, the interrup-tion of the transmission of bacteria, fungi, and virus has become a focus in SeaLife development, leading in an anti-infective polymer program.

— At the moment the company has 2 pat-ents accepted, 1 in submission, and 2 others filed.

Market

— Global market for MRSA is forecast to increase from $ 1.6bn in 2008 to $ 2.6bn in 2014.


— SLP0904 Antibacterial compound MRSA–Skin Infection

Preclinical

— SLP0905 Antibacterial compound Endocarditis

Preclinical

— SLP0901 Disinfection Pre-registration phase

SeaLife Pharma

Technopark 1 / Geb. B / EG3430 Tulln, Lower Austria, Austria +43 2 272 626 [email protected]

Products

Christoph Wiesner and Alexander Pretsch


S-TARget therapeutics is a biotech company founded in August 2010. It develops novel therapeutic vaccines to cure and prevent severe, life-threatening diseases that currently cannot be cured – including severe forms of allergy. The vaccines are based on a unique, proprietary technology platform that is capable of boosting patient’s immune system to cure various diseases in allergy and oncology. The lead candidate product, SG-100, is targeted against severe house dust-mite-derived allergies.

Company Profile


Management Team

CEO: Christof LangerCSO: Geert C. MuddeBD: Theodor Langer

Public Funding

aws PreSeed: € 160,000 aws Seed: € 1MFFG: € 0.3M

Technology

— House dust mites represent the world’s number one allergen, which leads to extremely severe forms of allergies.

— Unlike other drugs, S-TARget vaccines address the cause of the disease and not only the symptoms.

— The S-TARget technology platform is based on a 2-module system: a generic module (warhead) and a variable, dis-ease-specific module (immunogen).

— The entire S-TIR platform is protected by a patent family.

— Proof of concept of the platform tech-nology in allergy as well as oncology was successfully demonstrated in vitro as well as in vivo.

Market

— Allergies affect up to 30% of the Western population.

— The allergy treatment market currently shows revenues of about $ 3bn/year with a significant increase each year.

— Even the existing blockbuster allergy drug achieved a market share of only 2%, which shows the high unmet need for an appropriate treatment.

— In Europe, US, and Japan there are approx. 14 million patients diagnosed with severe allergic asthma derived from house dust mites, for whom currently there is no cure available.


— SG-100 Allergy Preclinical

— SG-200 Oncology Preclinical

S-TARget therapeutics GmbH

Mooslackengasse 171190 Vienna, Austria+43 664 516 003 [email protected]

Products

S-Target Management: Geert Mudde and Christof Langer


TAmiRNA is a Research & Development company (in incorporation) that develops novel tools for the diagnosis and treatment of age-associated diseases. To achieve these goals, TAmiRNA capitalizes on a strong background in microRNA (miRNA) research – tiny non-coding RNAs with important roles for tissue regeneration and body homeostasis – and focuses on translating this knowledge into effective tools for the personalized diagnosis and treatment of age-related bone and cardiovascular diseases.

Company Profile


Management Team

CEO, co-founder: Otto KanzlerCOO, co-founder: Matthias HacklCo-Founder, Scientific Advisor: Johannes GrillariCo-Founder, Scientific Advisor: Regina Grillari

Public Funding


Private Funding

Not disclosed

Technology

— Automated gene expression analysis from cells, tissues, and biofluids; pharmacog-enomics; stem cells and in-vitro models for functional microRNA analysis; preclinical model systems for drug research and development; IP on microRNA-31 as diagnostic and thera-peutic target for osteoporosis (see figure).

— Indication: Osteoporosis is among the most severe age-related diseases in the 21st century. Thus, there is a great need for highly reliable and validated prog-nostic and predictive test systems for risk assessment and for the development of individual therapy.

— Vision of TAmiRNA: Effective personal-ized treatment of age-related bone and cardiovascular diseases using miRNA applications.

— Technology: Conducting studies to screen miRNAs in blood samples from well-characterized clinical cohorts; Development of a non-invasive screening method for blood-circu-lating miRNAs; Development of diag-nostic kits for reliable prognosis of progress and risk of the disease; Drug development using microRNAs for therapy and treatment of age-re-lated diseases.

Products & Services

— TAmiRNA molecular Diagnostic Test for Osteoporosis Risk Assessment.

— Best-in-class research on miRNAs with focus on age-related bone and cardiovascular diseases.

Market

— The global therapeutic Osteoporosis market will reach $ 11.4bn in 2015.

— Customers – Industry: Global trade part-ners, companies in the field of health care and prevention.

— Customers – Clients: Companies and persons active in age-related health care and prevention, assessment and treatment of Osteoporosis and Osteo-penia; Patients suffering from bone and cardiovascular diseases.

Tamirna GmbH

Muthgasse 111190 Vienna, Austria+43 650 499 147 2 (scientific issues)+43 664 422786 1 (business issues)[email protected]

TAmiRNA technology


Themis Bioscience is a biotechnology company developing vaccines to prevent infectious diseases. The company´s development focus is primarily on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. The company is using its core lead technology, Themaxyn, to create novel vaccines. The product portfolio includes vaccines against dengue, chikun-gunya, and other viruses.

Company Profile


Management Team

CEO: Erich Tauber

Public Funding + Private

aws, FFG, Inits, Founders, Omnes Capital, Ventech: € 8.5M

Technology

— Themis’ core lead technology, Themax-ynTM, is a novel vaccine platform based on an approved and well-known mea-sles virus vaccine and developed by the world-leading Institut Pasteur.

— ThemaxynTM is used to stably present transgenes at the virus surface directly to macrophages and dendritic cells without causing immune responses against the vector itself.

— First vaccine targets are emerging trop-ical and travelers’ diseases, including vaccines against dengue, chikungunya, and other viruses.

— The ThemaxynTM technology can easily be expanded to further indications.

Market

— Global market for vaccines was $ 14bn in 2010, with an annual growth rate of 13%.

— Market for novel and improved vaccines has grown at an annual rate of 38%.

— Importantly, it has been demonstrated that immunization with a ThemaxynTM chikungunya virus construct confers 100% protection in a relevant animal model.

— Chikungunya vaccine has completed preclinical testing and will start phase I studies in 2013.

— Dengue vaccine has successfully under-gone non-human primates experiments and is about to enter clinical phase I in early 2014.

Products

Indication Stage of development

— A Dengue fever End preclinical phase – Start phase I

— B Chikungunya fever Phase I studies in 2013

Themis Bioscience GmbH

Muthgasse 11/21190 Vienna, Austria+43 1 236 71 [email protected]

Products

Themis offices and laboratories


The Siesta Groupis a comprehensive service provider supporting the meas-urement of sleep, wakefulness, and brain activity in clinical trials and research. This encompasses, among other things, high-quality services concerning polysomnography (PSG), pharmaco-electroencephalography (pharmaco-EEG) and event-related potentials (ERP). Services range from consul-tation, site selection, site training, centralized data scoring and analysis, data quality control, to device rentals.

Company Profile


Management Team

CEO: Georg DorffnerCSO: Peter AndererCFO: Peter Runa

Public Funding

aws Seed (2003): € 500,000aws TFP guarantees (2004): € 600,000EU project SENSATION (grants): € 215,500FFG (grants and loans in total): € 490,000

Private Funding

€ 1.9M

Technology

— The Siesta Group provides a technolog-ical platform for measuring brain activity, sleep, and vigilance in clinical trials and research. State-of-the-art as well as innovative signal processing software is at the core of this platform.

— The company has developed the Som-nolyzer 24x7® system, the world’s most efficient automated analysis system for sleep profiles based on polysomnog-raphy (biosignals measured in the sleep lab). For the diagnostic market, the software is now owned and marketed

by Philips Respironics. The Siesta Group employs Somnolyzer in clin-ical trials for utmost reliability in sleep measurement.

— The processes surrounding Somnolyzer 24x7 and the company’s EEG analysis tools, including secure and efficient internet-based transmission of data from the investigator site to the scoring center, serve as immediate data quality control and help ensure an efficient harmonization of measurement within and across sites.

Services

— Central data scoring, analysis, and delivery

— Equipment leasing — Site identification, feasibility, site training,

harmonization — Protocol consulting — Advanced analysis, biomarker research

Market

— The Siesta Group primarily targets the worldwide pharmaceutical research market for CNS-active drugs, espe-cially in early phase (I and II) as well as preclinical.

— Additional markets are academic research and medical device industry

The Siesta Group Schlafanalyse GmbH

Schlosshofer Strasse 11, 3rd floor1210 Vienna, Austria+43 1 955 12 [email protected]

The Siesta Group Service


Tissue Med Biosciences is a biotech company developing novel therapies for chronic diseases. Therapeutic developments (human recombinant proteins) from TMB target indications in the field of diabetic foot ulcer, hematology, and musculoskeletal diseases.

Company Profile


Management Team

CEO, Founder: Rudolf BergerCSO: Maximilian Berger

Public Funding

aws Seed: € 450,000aws Double Equity: € 685,000Others (FFG, Lower Austria): € 1.24M

Private Funding

Not disclosed

Technology

— Tissue Med Biosciences’ (TMB) lead development targets the indication of diabetic foot ulcer (DFU), a serious con-sequence of type 2 diabetes.

— The multifunctional recombinant pro-tein TMBP-3 has significant competitive advantages as it targets the three rel-evant factors for healing diabetic foot ulcers: wound closure, growth of new vessels, and activation of the immune system.

— The preclinical safety program was completed in 2013 and shows excel-lent tolerability in long-term toxicological studies.

— A clinical phase 1 study will be initiated in late 2013.

— TMBP-3 is formulated in hydrogel for topical application.

Market

— The market of chronic diseases is con-stantly growing, resulting from obesity and diabetes: more than 20 million dia-betic foot ulcer patients worldwide are waiting for a satisfactorily effective and easy-to-administer therapy (15% of all patients with type 2 diabetes develop a diabetic foot ulcer).

— Treatment of decubitus ulcers would be applicable worldwide to 9 million patients, while 8 million patients world-wide suffer from chronic venous ulcers and could be treated with TMBP-3.

— Pipeline developments target large and growing markets of a similar size (OECD 2011, The Lancet 2011).


— TMBP-3 Diabetic foot ulcer Preclinical

— TMBP-4 Hematology Under development

— TMBP-5 Musculoskeletal diseases Under development

Tissue Med Biosciences

Magnesitstrasse 13500 Krems, Lower Austria, Austria+43 2732 87470 - [email protected]

Products

Tissue Med Biosciences Research


TUBE Pharmaceuticals is a biotech company with a focus on small molecules derived from natural products for targeting approaches for safer and more efficacious therapies. The company is developing a pipeline of various products by using different targeting principles for conjugation to its toxin platforms, addressing major disease areas with unmet medical needs. The toxin platforms of proprietary Tubulysins (Cytolysins) and Epothilones are available for licensing.

Company Profile


Management Team

CEO: Wolfgang RichterCBO: Michael Ahrweiler

Public Funding

aws Seed: Not disclosed

Private Funding

Not disclosed

Technology

— The toxin platforms of proprietary Tubu-lysins (Cytolysins) and Epothilones are proven pay-loads for a variety of tar-geting approaches used by TUBE itself and by its licensees.

— TUBE’s own development product is a nanopharmaceutical using a tubulysin as its active principle, which shows an excellent efficacy and safety profile in many in-vivo studies.

— TUBE has licenses for natural tubu-lysins/cytolysins and epothilones and holds its own IP on these compound classes.

Market

— The market volume for conjugation products is in the multibillion euro range. The key indication areas are especially oncology and hematology.

— TUBE also offers synthesis services for complex organic molecules, e.g. toxic payloads, linkers, building blocks.


— Poly-CD-PEG-Tub Oncology / Hematology Preclinical

— Cytopep Oncology Preclinical

TUBE Pharmaceuticals GmbH

Leberstr. 201110 Vienna, Austria +43 1 740 935 [email protected]

Products


ugichem Based on the innovative Ugimer® platform, ugichem is developing innovative antisense therapeutics with a unique therapeutic efficacy profile for immune-mediated inflamma-tory diseases (IMID), where existing therapies are insufficient or do not work. ugichem primarily focuses on rheumatoid arthritis (RA) as lead indication.

Company Profile


Management Team

CEO: Holger Bock CSO: Thomas Lindhorst CTO: Jürgen Soutschek

Public Funding

aws Seed: € 1MFFG: € 1.9M

Private Funding

€ 6.75M

Technology

— Antisense drugs are assessed to become the next major breakthrough in molecular medicine. The first product has entered the market and numerous new antisense drugs are currently in clinical development. However, the standard, RNA-based, antisense con-cepts have failed so far in the IMID field. The reasons are insufficient activity in immune-system-relevant organs and cells in combination with unspecific immune system stimulation.

— Ugimers are non-RNA-based antisense drugs with a unique combination of delivery, efficacy, and safety parameters confirmed to provide a new and more specific therapeutic efficacy profile for immune-mediated inflammatory dis-eases with high medical need.

— Ugimers are protected by a broad patent portfolio, exclusively owned by ugichem.

Market

— The global rheumatoid arthritis market was $ 18.6bn in 2012 and is expected to grow from to $ 26bn in 2017.


— Ugi-RA Rheumatoid arthritis Preclinical

— Ugi-IMID Immune-mediated inflammatory diseases

Preclinical

ugichem GmbH

Mitterweg 246020 Innsbruck, Tyrol, Austria+43 512 282 285 [email protected]

Products

ugichem offices and laboratories


Valericon develops novel drugs to improve patient outcomes in the therapeutic areas of anxiety and epilepsy. Valericon’s strength is the proprietary screening technology enabling rapid identification of drug candidates from plant extracts or chemical libraries. We develop a novel class of specific GABAA receptor modulators based on a natural compound isolated from valerian roots as potential anxiolytics and anticonvulsants.

Company Profile


Management Team

CEO: Steffen Hering

Public Funding


Technology

— Subunit-specific modulators of GABAA receptors are expected to exhibit a more selective therapeutic profile with fewer side effects than the widely used benzodiazepines.

— Valerenic acid from Valerian root extracts is a natural product that causes anxiolysis without sedation. It binds with nanomolar affinity and interacts selec-tively with GABAA receptors comprising 3 subunits.

— Neurons expressing GABAA( 3) recep-tors are the molecular target for novel anxiolytics that do not cause sedation.

— VAD1 and VAD2 are small molecules interacting specifically with GABAA receptors comprising 3 subunits. VAD1 and VAD2 cause anxiolysis without sedation. This mechanism was proven in vivo in a mutant mouse model.

— Valericon has applied for patents on several subunit-selective GABAA receptor modulators.

Market

— There is an unmet demand for novel drugs to treat anxiety, one of Valericon’s major therapeutic targets. The global anxiety disorders market is predicted to grow to $ 5.1bn in 2017 in the US and the five major European markets.

— Valericon will focus on the European and US Markets.

— Valericon’s business model stands on three pillars, all of them make use of the core screening competence: 1. Development of valerenic acid and derivatives as a class of novel-specific modulator of GABAA receptors 2. Collaborative drug screening program (service for fee) 3. HERG screening (service for fee)


— VAD1 Anxiety, epilepsy Preclinical

— VAD2 Anxiety, epilepsy Preclinical

Valericon GmbH

Leidesdorfgasse 14/TOP 61190 Vienna, Austria +43 664 820 074 2 [email protected] www.valericon.com

Products

Valericon technology


Valneva is an European biotech company dedicated to vaccine development and antibody discovery for the treatment of infectious diseases. It was created in 2013 through the merger between Intercell AG and Vivalis SA. Valneva gener-ates diversified revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®), and licensed technology platforms. It has more than 35 research and commercial agreements with the world’s largest pharmaceutical companies.

Company Profile

Founded: 2013 (1997 Intercell AG) Legal Form: GmbH (Valneva Austria GmbH is a subsidiary of Valneva SE)Employees: ~140

Management Team

CEO: Thomas LingelbachCBO: Franck GrimaudCFO: Reinhard KanderaCSO: Majid Mehtali

Public Funding

(Intercell AG 1997-2012) aws Seed: € 725,000erp/ FFF/ FFG/ ZIT: € 27,570,000

Private Funding

€ 484,000,000

Technology

— IXIARO® / JESPECT® Japanese Encephalitis Vaccine

— EB66® Vaccine Production Platform derived from duck embryonic stem cells

— VIVA|Screen™ Antibody Discovery Plat-form for fully human therapeutic mAbs

— IC31® Adjuvant for Vaccines

Market

— Vaccine for travelers to endemic regions; also distributed to US military. Long-term potential of in-market sales of ~€ 200M. Partners: Novartis, CSL, Biological E.

— Partnered with several companies. First veterinary vaccine approved in 2012; NDA filed for first human vaccine in 2013 (Partner Kaketsuken).

— A collaborative & commercial agreement with Sanofi Pasteur on several infec-tious targets: up to € 200M milestones/ royalties.

— Adjuvant can be used to improve vac-cines in different indications. The most advanced studies are in TB.


— IXIARO® / JESPECT® / JEEV®

Japanese Encephalitis

Marketed

— EB66® Vet. Vaccines

e.g.: Egg Drop Syndrome

Approved vet. vaccine on EB66® (w/ Kaketsuken)

— EB66® Human Vaccines

e.g.: H5N1 Pandemic Influenza

Regulatory approval (JP, w/ Kaket-suken) / Phase II (US, w/ GSK)

— IC43 Vaccine Candidate

Pseudomonas aeruginosa

Phase II/III (co-funding by Novartis)

— IC31® Partnered Programs

e.g.: Tuberculosis 3 TB candidates in Phase II and Phase I (w/ SSI, Sanofi)


Clostridium difficile Phase I in house, Novartis option


Lyme Disease Preclinical

Products

Valneva Austria GmbH

Campus Vienna Biocenter 31030 Vienna, Austria+43 1 206 [email protected]

Valneva research


Vela Laboratories is a GMP-certified contract laboratory offering protein char-acterization services to the pharma and biotech industries. The company focuses on the analysis of biopharmaceu-ticals, biologics, and biosimilars at all stages of product development, from preclinics up to market approval.

Company Profile


Management Team

CEO: Markus FidoCOO: Andreas NechanskyCFO: Armin Franz

Public Funding

aws Seed: € 275,000ZIT/LISA: € 670,000

Private Funding

€ 1.5M

Technology

— Vela is a partner for process devel-opment during early phases (preclin-ical development, GLP), during clin-ical development (GCP/GMP), and up until product release and submission (GMP, method validation, stability studies, batch release).

— Vela is a partner for preclinical and clinical development and consulting (study analytics and organization…) with emphasis on pharmacology, pharmacokinetics, pharmacody-namics, and immunogenicity testing (ADA´s), as well as bioequivalence and ADME studies.

Market

— Support for market authorization appli-cation of biosimilars:

— In 2012, more than 15 different proteins (mAbs, rhu-proteins, peptides) were in the development pipeline.

— Clients: 18 (Austria, Europe, USA/Canada, India)

— Vela’s sales are growing rapidly and consistently: 2007: € 300,000 2008: € 600,000 2009: € 900,000 2010: € 1,900,000 2011: € 2,200,000 2012: € 2,700,000

Product & Services

— Physico-chemical analysis — Immunological and immunochemical

methods — Bioassays: potency, efficacy, stability — Pharmaceutical technical procedures

and Pharm. EU methods for API, DS, DP

— Analytical support for preclinical and clinical trails (PK, PD, bioequivalence studies)

Vela pharmazeutische Entwicklung und Laboranalytik GmbH

Brunner Straße 69/31230 Vienna, Austria+43 1 890 597 [email protected]

Vela Management: Andreas Nechansky, Markus Fido, Armin Franz

— Method validation according to ICH guidelines

— Storage and logistics under GMP conditions

— Stability studies, accelerated studies, L&E studies

— Batch release in the EU by a qualified person


ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, “VSV-GP,” efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics’ team is currently performing preclinical safety and efficacy studies for VSV-GP and aims to conduct initial clinical trials in cancer patients in three years.

Company Profile


Management Team

CEO: Ludwig Weiss (co-founder)CSO: Dorothee von Laer (co-founder)

Public Funding

aws PreSeed: € 182,000CAST: € 18,000

Technology

— Oncolytic viruses (OV), which prefer-entially replicate in cancer cells and thereby destroy cancer tissue, are a highly promising novel class of anti-cancer biopharmaceuticals.

— ViraT’s OV VSV-GP has been shown to be highly effective in, or even cure (!), all cancers tested so far in mouse models.

— VSV-GP is the first OV that does not induce neutralizing antibodies to the virus itself and therefore allows repeated systemic application without loss of efficacy.

— Thus, VSV-GP therapeutics have the potential to revolutionize cancer therapy.

— ViraTherapeutics holds patents and patent applications to protect the unique VSV-GP technology in all the major pharmaceutical markets.

Market

— The global market for cancer drugs was € 41bn in 2010 and is estimated to be around € 60bn by 2016.

— As conventional treatment regi-mens reach their limits, there is an urgent need for new effective cancer therapeutics.

— The first two target cancers addressed by ViraT will be melanoma and brain cancer. The melanoma market in the seven major pharmaceutical countries is estimated to grow with a compound annual growth rate of ca. 9% from € 1bn in 2012 to about € 2bn in 2021. There is also a strong potential opportunity for new drugs to enter the market for brain tumors; a market which is expected to reach € 1bn in 2016 in the seven major pharmaceutical markets.


— VSV-GP Melanoma Preclinical

— VSV-GP Glioblastoma Preclinical

ViraTherapeutics GmbH

Peter-Mayr-Str. 4b6020 Innsbruck, Tyrol, Austria+43 699 190 855 [email protected]

Products

ViraT Team: Ludwig Weiss and Dorothee von Laer (center)


Xiber Science is improving Survival & Outcome of Critical Care & Trans-plant Patients. Up to 50% of critical care patients are affected by organ failure – 40% of them die; 37% of the survivors stay handicapped for life. 20-40% of transplant patients suffer from primary graft dysfunction (PGD). PGD is the leading cause of early death after transplantation. To date, no specific treatment to prevent organ failure is available. Xiber develops first-in-class peptide drugs that prevent organ damage/failure.

Company Profile


Management Team

CEO: Sonja ReingruberCSO: Peter PetzelbauerCFO: Michael Hoffmann

Public Funding

aws Seed: € 500,000Others: € 200,000

Technology

— The breakdown of endothelial and epi-thelial barriers is a major contributor to the pathogenesis of many inflammatory, infective, cardiovascular and cancerous diseases.

— Xiber has developed a high-content assay (HCA) to screen for substances that protect endothelia and epithelia from breakdown.

— Employing our HCA, we have identified synthetic peptides that prevent organ failure.

— Patents: 2011 PCT, 2012 national phases initiated in USA, CA, EU, CN, RU, and JP

Market

— Initially, Xiber will concentrate on indica-tions (see below) with a market volume of $ 600M

— In the medium term, Xiber aims to develop a prophylactic treatment for critical care and transplant patients.

— To date, there is no approved drug on the market to prevent organ failure.


— Xib13-01 Acute lung injury Preclinical

— Xib13-02 Transplantation Preclinical

— Xib13-03 Severe burns Preclinical

Xiber Science

Josefigasse 242353 Guntramsdorf, Lower Austria, Austria+43 699 170 540 [email protected]

Products

Xiber’s high-content assay


XworX – The App Store for Bioinformatics. High throughput technologies in life sciences, leading to rapid progress in personalized medicine and biotechnology, impose a great challenge in data handling and the extraction of the relevant biological and medical information. Responding to this demand, we provide an app store and a cloud-enabled software platform for community driven app development as well as the corresponding marketplace.

Company Profile


Management Team

CEO: Albert Kriegner CTO: Visne Ilhami

Public Funding


Technology / Innovation

— Dynamic Apps: XworX implements an extended app model that integrates all components like workflow, cloud-en-abled services, data logging, and reporting within any single app, pro-viding auto-deploying, easily portable, and ready-to-use compact software solutions. This makes it ideally suited for the specific requirements of life sciences applications:

— Auto-deployment, no configuration effort — Full support of big data, security, data

logging, and advanced data mining — Access to tools and data anywhere:

desktop, mobile, web client

Market

— The global bioinformatics market was $ 2.3bn in 2012, forecasted to reach $ 9.1bn in 2018, at a CAGR of 25.4% from 2012 to 2018.

— Bioinformatics platforms have the largest market share with nearly 50% of the market revenue.

— This segment is also the fastest-growing market with an estimated 54% of the total market growth from 2012 to 2018.


— Next Generation Software Platform & Apps

Our “dynamic apps concept” provides easily portable, ready-to-use solutions. Our comprehensive software environ-ment simplifies the app development, enabling even non-IT experts (life scienc-es researchers, statisticians, bioinforma-ticians,…) to develop high-quality, com-mercial apps directly from their research tools and to share and commercialize them via our app store.

— Next Generation Market Place A marketplace for apps, app developers, and crowd-funding of app projects. It will facilitate community-driven app devel-opment, wiki documentation, and expert review.

XworX

Muthgasse 111190 Vienna, Austria+43 699 194 605 [email protected]

Services

CEO, Albert Kriegner


Zytoprotec is a biotech company that specializes in “cell protection / cell repair” and was founded in February 2007. The company is currently focusing on cytoprotection with the first innovative product for renal therapies: PD-Protec. The lives of millions of people/patients worldwide can be saved or improved in the long run by these patent-protected research results. Additional products and research areas in the field of cytoprotection are already being planned.

Company Profile


Management Team

CEO/CFO: Michael HoffmannCSO: Christoph Aufricht

Public Funding

aws Seed: € 1.0MOthers (FFG, ZIT): € 2.53M

Private Funding

€ 6.0M

Technology

— Most advanced product candidates focus on the treatment of patients suf-fering from kidney failure. For these patients, peritoneal dialysis (PD) is an established treatment option.

— PD improves quality of life and reduces costs incurred to the health care system in comparison to hemodialysis (HD).

— Zytoprotec’s preclinical research and the recently completed Phase I/II trial have demonstrated that the cytoprotec-tive effects of PD-Protec™ promise to protect the peritoneum from damages caused by commercial PD-fluids. Patent: PD-Protec™ is based on PCT/AT2008/000072 - WO 2008/106702 European patent was granted 23 October, 2012.

Market

— Overall, the size of the global dialysis market was approx. $ 75bn

— in 2011 with approx. $ 62bn attributable to the segment dialysis services and approx. $ 13bn to the segment dialysis products.

— Based on information available, com-panies operating in the global dialysis market have shown an average share price increase of 40% over the last 5 years, while spending only about 5% of revenues on R&D.

Products Indication Stage of develop-ment

— PD-Protec™ Dialysate with a cytoprotective effect to reduce major complications of PD treatment

Phase I/II

— Ico-Protec™ Cytoprotective glucose-free PD-fluid Preclinical

— OMNI-Protec™ up-regulating the cellularstress response in endothelial cells as novel treatments for diabetics that also suffer from hypertension

Preclinical

Zytoprotec GmbH

Stadiongasse 2/131010 Vienna, Austria+43 1 40 620 [email protected]

Products

Zytoprotec research

106 107

MedtechLocated in the heart of Europe, Austria has one of the world’s best healthcare systems. Along with high-class clinics, excellent research facilities and well-trained doctors, it is also based on superb equipment incorporating state-of-the-art technology. Not only does this make Austria an attractive market for medical technology products, it also makes it an important location for development and production which benefits from a long tradition in the field of engineering and precision mechanics.

108 Medtech – 109

4a medicom has developed a capillary microfluidics technology, which allows minimally invasive, safe, pain-free, fast, and easy testing of blood components. The system enables patients suffering from diabetes to quickly self-monitor their blood glucose levels. Contrary to the usual measuring methods employed today, which require the handling of several separate components, the 4a medicom product integrates lancing device, lancet, and test strip into one easily oper-ated disposable product—the “GlucoPearl”— so measure-ment can be done in one single step: “Measuring at the push of a button.” Basically, the GlucoPearl product has been conceived as “PEARL” platform technology and can be used in the future for various target groups depending on the customer’s requirement.

Company Profile


Management Team

CEO, founder: Reinhard Hafellner CFO: Sylvia Fauland CCO: Thomas Exel

Public Funding

aws: € 1MOthers (FFG, SFG, EFRE): € 4.3M

Private Funding

€ 6.1M

Technology

— GlucoPEARL combines lancing unit, lancet, and test strips all in a single device. “Measurement at the push of a button.”

— Easy-to-use, safe, pain-free, minimally invasive device analyzes quickly and delivers an all-in-one application for medical diagnostics as well as for sport medicine and wellness applications

— Integrated lancing, blood acquisition, and detection in a single disposable unit (one-step consolidated testing unit)

— Thin-film capillary microfluidics tech-nology uses nanoliter quantities of whole blood

— Screening via visual test strip — Photometric analysis of glucose levels

and subsequent monitoring via mobile phone are being developed

— GlucoPEARL and all planned product generations that build on its technology, have comprehensive patent protection.

Products Application Stage of development

— GlucoPEARL Blood Glucose Monitoring System IVD II/B Preclinical

4a medicom GmbH

Industriepark 18772 Traboch, Styria, Austria+43 384 2451 066 [email protected]

Products

4a medicom product

Market

— According to the WHO, the prevalence of diabetes will increase to 370M (4.5% of the global population) in 2030. The world market for blood glucose mon-itoring systems is estimated at $ 9bn (2012) with annual growth rates of ~7%.

— The greatest relative increases of dia-betes will occur in the Middle Eastern, sub-Saharan Africa, and India.

— For sales: A distinction must be made between two major target markets: (1) Point-of-Care Market (POC) – professional users in medical practices, hospitals, and nursing services, and (2) Self-Monitoring of blood-glucose market (SMBG) – patient’s own meas-urement. 4a medicom’s first target market will be the POC market with a subsequent launch in the SMBG market.

110 Medtech – 111

AFreeze The CoolLoop® cryoablation catheter makes treatment of atrial fibrillation simple, safe and successful

Company Profile


Management Team

CEO: Gertraud UnterrainerCTO: Gerald FischerCMO: Florian Hintringer

Public Funding

aws PreSeed + Seed: € 1.1MOthers (FFG, CAST, EFRE, Standortagentur Tirol…): € 1.4M

Private Funding

€ 2M

Technology

— Treatment of atrial fibrillation by cath-eter ablation is a lengthy and complex procedure.

— AFreeze has developed a novel cryo-ablation system to treat atrial fibrillation. Instead of using heat, AFreeze uses cry-oenergy to induce long circular lesions in the heart. The system is extremely simple to use (single-shot device) and safe. In addition, the loop form of the catheter enables new treatment modalities.

— The CoolLoop® system has success-fully concluded a clinical study in two study centers in H1, 2013.

— AFreeze owns six distinct patent families.

Market

— The global market for electrophysiology is worth USD 2.4bn (2012).

— It shows double-digit growth rates, driven by an ageing population, an increased usage of catheter ablation, and an increasing number of specialized centers performing such procedures.

— More than 4.5M people are affected by atrial fibrillation (AF) in Europe.

— The number of AF patients in Germany has increased by 73% over the last 15 years.


— CoolLoop® Catheter ablation of atrial fibrillation

Phase III Approved / in Approval procedure

— Tip-Catheter Atrial fibrillation, other arrhythmia

Phase III / Under development

AFreeze GmbH

Eduard Bodem Gasse 86020 Innsbruck, Tyrol, Austria+43 512 209 012 [email protected]

Products

AFreeze technology

112 Medtech – 113

Anagnostics provides diagnostic DNA and protein (e.g. antibody) test kits for complex diagnostic demands by offering an automated and integrated microarray technology (single device) for testing serum, plasma, urine, saliva, or liquor. Anagnostics focuses on integrated sepsis diagnostics by providing early multiplexed pathogen detection (4 h) from whole blood and therapeutical monitoring of a multitude of biomarkers.

Company Profile


Management Team

CEO: Christoph Reschreiter CSO: Bernhard Ronacher

Public Funding

aws PreSeed + Seed: € 600,000Others: € 130,000

Private Funding

€ 320,000

Technology

— Hyborg system including device, soft-ware, and consumables for applica-tions such as: highly paralleled DNA tests based on Anagnostics’ proprietary compact sequencing technology; highly paralleled immunotests based on Anag-nostics’ proprietary compact profiling technology

— Clinical test for early pathogen detec-tion from whole blood (sepsis): bacteria, fungi, and antibiotic resistances.

— Companion Diagnostics tests for muta-tions in the KRAS, BRAF, and EGFR gene

— DNA and protein microarray technology allows simultaneous analysis of several hundreds of DNA or protein markers in a minimal sample (e.g. 100µl plasma)

— Combination of real-time analysis and flexible sample processing (temperature, liquids) yields “high-content” data of a multitude of markers

— Hyborg is the first fully automated all-in-one device integrating a thermocycler, hybridization station, and fluorescence scanner for real-time (kinetic) DNA and protein microarray analysis

— Precise, fast, inexpensive, and simulta-neous testing of DNA or protein markers in a sample is carried out in a cylindrical microarray called hybcell

Market

— $ 4bn in 2010 (Molecular Diagnostics) CAGR of 11%

— Addressing additional markets with pro-tein-based tests (inflammation markers)

— Exponential growth of sales has been established


— Bacteria testing Sepsis IVD, marketed

— Fungi testing Sepsis IVD, RUO

— Antibiotic-resistance testing Sepsis IVD, under development

— Monitoring inflammation Sepsis IVD, marketed

— KRAS, BRAF testing Companion diagnostics IVD, marketed

— EGFR testing Companion diagnostics IVD, RUO

Anagnostics Bioanalysis GmbH

Westbahnstrasse 554300 St. Valentin, Lower Austria, Austria+43 7435 [email protected]

Products

Anagnostics technology

114 Medtech – 115

CVTec focuses on developing software tools for neurosurgery and neuroradiology, to enable physicians to concentrate on their core business and to improve life-saving operations. CoilControl3D is the first tool to automatically derive the only known success parameter of cerebral aneurysm operations instead of the actually subjectively biased estimations.

Company Profile

Founded: in progressLegal Form: GmbHEmployees: 4

Management Team

CEO, CTO: Georg MachCEO, CSO: Camillo SherifCEO, CFO: Thomas Ruhm

Public Funding

aws PreSeed: € 165,000INiTS: € 35,000

Private Funding

€ 135,000

Technology

— Cerebral aneurysms are balloon-like malformations of brain arteries with the risk of rupture and life-threatening bleeding. To prevent the rupture, physi-cians fill out the aneurysm with micro-coils. But the only known success parameter of this procedure is currently estimated by the attending physician. This leads to an overestimation by up to 30%, which results in very dangerous situations for patients.

— CoilControl3D is a software to calcu-late this parameter from automatically derived 3D reconstructions. Thus, we achieve a reduction in the complica-tion rate as well as an improvement in the treatment quality. The patients as well as the physicians and cost bearers benefit from this tool. Further products like CoilAlarm (minimizing risk of stroke), FlowControl (blood flow analysis) and RiskControl (patient-specific rupture risk analysis) are in the development pipeline.

— Two patents are pending; further pat-ents are in development.

Market

— In Europe there are about 72,000 micro-coiling procedures per year. The use of the software will be charged as a ser-vice, with a total market volume of about € 86M per year in Europe.

— Due to the increasing availability of CT and MRI, the number of procedures and examinations is rising. Like in Japan, comprehensive scans will lead to an enormous rush demand on coiling oper-ations and increase the necessity for patient-specific risk assessment.

— Insurance companies have estimated the annual socioeconomic costs of aneurysm rupture to be about € 1.9bn for Germany alone.


— CoilControl 3D Cerebral aneurysms IIb, under development

— CoilAlarm Cerebral aneurysms IIb, under development

— FlowControl Cerebral aneurysms IIb, under development

— RiskControl Cerebral aneurysms IIb, under development

CVTec Cerebrovascular Technologies GmbH

Mariahilfer Strasse 136/1.101150 Vienna, Austria+43 1 236 728 951 [email protected]

Products

CVTec Management team: Georg Mach, Thomas Ruhm, Camillo Sherif

116 Medtech – 117

Dioptex is an innovative medical technology company located in Austria, the center of Europe. The company was founded by Albert Daxer as a research and development company in 2003. The focus is mainly on research and development in eye surgery and ophthalmology. The technology is a “spin-off” of Daxer´s scientific work at the Department of Ophthalmology, Medical University of Innsbruck, Austria. The innovative products of DIOPTEX are manufactured almost exclusively in Austria and distributed worldwide.

Company Profile


Management Team

CEO: Albert DaxerSales + Marketing: Erwin Weglehner

Public Funding

aws Seed: € 500,000 Others: Not disclosed

Private Funding

Not disclosed

Technology

— The novel corneal intrastromal implanta-tion surgery (CISIS) is a minimally inva-sive technology to correct short-sight-edness (myopia) and keratoconus, a degenerative corneal disorder.

— CISIS allows treatment of the entire range of myopia and keratoconus including cases beyond 8 diopters, but without the need of intraocular surgery.

— Dioptex has developed a PocketMaker® microkeratome to generate a closed corneal pocket that allows the insertion of the MyoRing®.

— The MyoRing® is a permanent con-tact lens, which is squeezed into the cornea slightly underneath the cornea surface. The MyoRing® is developed and designed for the treatment of kera-toconus and myopia up to almost 20 diopters.

Market

— World market for implantable contact lenses (CISIS) was estimated up to € 6bn in 2005 with a market potential of 1.5bn patients.


— Pocketmaker Corneal surgery IIa, marketed

— MyoRing Keratoconus, myopia IIb, marketed

Dioptex GmbH

Baumbachstraße 64020 Linz, Austria+43 732 774 [email protected]

Products

Dioptex product

Service

— CISIS technology training

118 Medtech – 119

DirectSens is dedicated to the development of carbohydrate biosensors that can be used for medtech and industrial applications. Based on over 10 years of extensive research, we devel-oped a technology platform for 3rd generation biosensors. The great flexibility of our technology, combined with the simple architecture of the biosensors, allows us to precisely meet the requirements of our customers.

Company Profile


Management Team

CEO: Christoph Sygmund, Roman KittlCFO: Gerald SchauflerCofounders: Christoph Sygmund, Roman Kittl, Alfons Felice, Wolfgang Harreither, Roland Ludwig

Public Funding

aws PreSeed: € 140,000Others(accent): € 60,000

Private Funding

€ 68,000

Technology

— Biosensors are analytical devices used for the detection of an analyte with the help of a highly sensitive biological component.

— DirectSens develops biosensors for sin-gle-point as well as continuous meas-urements of glucose in blood and of other sugars for various industrial applications.

— The patented core element of the DirectSens technology is the enzyme Cellobiose Dehydrogenase.

— By exploiting the natural function of the biocatalyst, DirectSens can realize a simple sensor architecture, omitting any additional elements necessary in con-ventional biosensors.

— This DirectSensing approach results in highly accurate sensor performance combined with simple manufacturing.

— Two patents filed.

Market

— Diabetes is a metabolic disorder causing dangerous blood glucose fluctuations, forcing patients to measure their blood glucose level several times a day. The global market for blood glucose mon-itoring systems was $ 9bn in the year 2010 with a CAGR of 6.6% since 2005.

— Besides the diabetes market, DirectSens targets emerging business segments for biosensors such as the fast-growing 2nd generation bioethanol market or the dairy industry with a focus on lac-tose-free products.


— Blood glucose test strips

Blood glucose monitoring GMDN 30221 class IIa, under developement

— Continuous blood glucose monitoring system

Blood glucose monitoring GMDN 34220 class III, under developement

— Lactose/cellulose test strips

Process control Under developement

DirectSens GmbH

Am Rosenbühel 383400 Klosterneuburg, Lower Austria, Austria+43 699 [email protected]

Products

DirectSens biosensor technology

120 Medtech – 121

EMCOOLS Medical Cooling Systems is a rapidly growing Austrian medical device company with the mission to improve the quality of patient care during therapeutic cooling. The unique and patented HypoCarbon® Technology Pads provide outstanding cooling rates for fast and efficient patient cooling and are able to cover the whole cooling chain from the pre-hospital ambulance service / air rescue through to the in-hospital setting. Indications for cooling therapies are cardiac arrest, myocardial infarction, stroke, sepsis and various hyper-thermic diseases.

Company Profile


Management Team

CEO: Michael Kühling

Public Funding

aws Seed: € 500,000aws Double Equity: € 1.19MOthers (FFG): € 44,000

Technology

— HypoCarbon®, the patented EMCOOLS technology for easy and efficient cooling, ensures that the surface cooling systems EMCOOLS Brain.PadTM and Flex.PadTM provide highly efficient cooling rates of up to 3.3 °C per hour.

— The thermal conductivity (“cooling velocity”) of HypoCarbon® is 15 x higher than that of ice and 58 x higher than that of water.

Market

— Product clearance in Europe, US, Brazil, China, and Japan. By summer 2012, more than 100,000 pads had been used worldwide to the benefit of more than 10,000 patients.

— Distribution partners in more than 40 countries worldwide.


— Flex.PadTM TH/TR Class IIa E (=Europe), approved

— Flex.PadTM Small TH/TR Class IIa E, approved

— Brain.PadTM TH/TR Class IIa E, approved

— Brain.PadTM Small TH/TR Class IIa E, approved

— Air.Pack TSS Class I E, approved

— Six.Pack TSS Class I E, approved

— Six.Pack XL TSS Class I E, approved

— Box TSS Class I E, approved

EMCOOLS Medical Cooling Systems AGBruckner Straße 6/7a1040 Vienna, Austria+43 225 289 015 [email protected]

Products

TH/TR: Therapeutic Hypothermia / Temperature Reduction TSS: Transportation and storage system

Emcools Medical cooling pads

122 Medtech – 123

EMTensor is a medical device company that researches and commer-cializes electromagnetic (microwave) imaging technology and products for biomedical use using safe levels of electromag-netic fields from the non-ionizing spectrum. The company researches and develops novel 4D electromagnetic imaging technology and devices, unifying anatomical and functional capabilities in a single technology. The mobility of the tech-nology will enable its use in different areas (ambulance, rescue helicopter, rural area, etc.). The company addresses the growing demand for cost-effective, safe, and mobile imaging technol-ogies needed for a wide range of medical applications such as stroke, brain injuries, and various types of cancer and body injuries. The most advanced project of generation 1 is currently undergoing clinical trials with stroke patients.

Company Profile


Management Team

CEO and founder: Serguei Semenov

Public Funding

aws Seed: € 750,000

Technology

— The biological object is within EM fields and is created by a plurality of trans-mitters. Sensors measure complex EM fields affected by the presence of the biological object. Highly sophisticated algorithms are used to inverse a “data tensor” and reconstruct a 3D distribu-tion of dielectric properties within bio-logical objects to obtain an image of the object. Technically, EMT technology works in a similar fashion as traditional tomographic imaging modality. How-ever, instead of a measurement of char-acteristics based on X-ray radiation (as

in CT), EMT sensors measure com-plex scattered EM field (amplitude and phase). The level of EM field used in imaging procedures is less than the level of EM field used in cell phones. This is a technique that is non-invasive, mobile, easily applied, and can monitor the patient continuously in real-time, either at the bedside or in the emergency department.

— More than € 155,000 has been invested for protecting the intellectual property only. EMTensor has five issued patents and nine patents pending.


— BrimG1 Stroke Class IIa

EMTensor GmbH

Donau-City-Strasse 11220 Vienna, Austria+43 1 890 661 [email protected]

Products

Market

— EMTensor GmbH addresses a market of approximately 15 million people suf-fering stroke worldwide every year. Of these, 5 million die and another 5 mil-lion are permanently disabled. Stroke in Europe accounts for 1.1 million deaths per year. Stroke together with cardiac infarct is also the leading cause of death in Austria. By reducing the time to treat-ment, the average 5-10% (depending on the country) DALY´s lost by stroke could

be reduced. Stroke is a leading cause of disability affecting physical, cognitive, communicative, and social domains. Stroke is responsible for a burden of about 2.2% of total health costs.

— Medical imaging equipment market rev-enue is estimated to grow at a CAGR of 4.4 % from 2012 to 2017.

— EMTensor GmbH’s first target market will be Europe and USA.

124 Medtech – 125

Ergospect specializes in the development and production of diagnostic pedals for the examination of different muscle groups, the myocardium, and the musculoskeletal system, to simulate stress situations or physical exercise inside the MRI bore.

Company Profile


Management Team

CEO: Thomas HuglCSO: Michael Schocke

Public Funding

aws PreSeed: € 55,000aws Seed: € 400,000Others (CAST, Land Tirol K-Regio): € 645,000

Technology

— The diagnostic pedals produce phys-ical stress within the MRI bore. Exam-inations are simultaneously monitored and evaluated by highly sophisticated analytical software. Based on the imple-mentation of various MR technologies, numerous biological parameters can be measured under physiological and pathological conditions.

— The devices are pneumatic and work with optosensors. They are easy to use in a daily clinical routine and compatible with any MRI up to 9 Tesla and higher.

— Ergospect holds patents in Germany, UK, France, USA, India, and China.

Market

— In 2008, the global market for MRI ergometry accounted for over $ 3bn. The estimated annual growth rate is approx. 10%.

— Developed countries show growing sensibility toward diagnoses in the field of vascular surgery, orthopedics, angi-ology, cardiology, and sports medicine. Effective methods like the Ergospect devices for dynamic MRI stress testing will be in demand in order to detect cer-tain indications accurately.

— Ergospect’s primary target markets are Europe, North America, and Asia. The company benefits from close scientific cooperation with different leading inter-national university institutes.


— Trispect® Module Calf muscle Class I, approved

— Quadspect® Module Quadriceps muscle Class I, approved

— Glutspect Module Gluteus muscle Class I, approved

— Cardiologic Module Cardiovascular system Class I, approved

— Orthospect® Module Musculoskeletal system (joints and spine)

Class I, under development

Ergospect GmbH

Oppolzerstraße 66020 Innsbruck, Tyrol, Austria+43 699 160 202 [email protected]

Products

Ergospect diagnostic pedals

126 Medtech – 127

impress strives for the implementation of a simple-to-use, reliable system for non-invasive continuous blood pressure meas-urement as a new clinical standard: Patients will be spared pain and the risk of complication while health care providers will be able to better monitor their patient’s status and thus improve patient outcomes and save costs.

Company Profile

Founded: 2013Legal Form: e.U.Employees: 1

Management Team

CEO: Arnulf HellerChristopher ArbeiterEva GrieshuberBernd HöflerMartin Götting (fundraising)

Public Funding

aws PreSeed: € 200,000FFG Basis: € 170,000

Technology

— 20% of all surgeries, or more than 50 million, per year worldwide – from Cesarean section to hip replacements – require continuous blood pressure monitoring. Until today, no non-invasive method exists that is suitable for clinical practice, thus making monitoring this vital sign unnecessarily painful, risky, time–consuming, and expensive.

— impress provides continuous non-in-vasive blood pressure measurement utilizing a cheap, robust, and clinically well-known setup. impress ties easily into existing multi-parameter monitoring equipment and requires practically no instrumentation training, thus allowing for fast acceptance as the clinical standard.

— impress technology is patented in Europe (PCT/EP2010/062873), with applications in US and Japan.

Market

— The global market for non-invasive, con-tinuous blood pressure measurement devices in 2013 is estimated at € 1.3bn.

— Disposable electrodes represent sub-stantial potential.

— impress builds its GTM strategy around clinical application areas with high potential and considerable size, geo-graphically in Europe and markets with high demand, to enhance health care and to face challenges where non-inva-sive methods are preferable and where reasonable market entrance hurdles exist.


— Impress BP Monitor Non-invasive continuous clinical blood pressure monitoring

Class IIb, under development

Impress MedTech e.U.

Plüddemanngasse 398010 Graz, Styria, Austria+43 664 [email protected]

Products

impress Team: Arnulf Heller (center left), Christopher Arbeiter (center right), Eva Grieshuber, Bernd Höfler

128 Medtech – 129

iSYS Medizintechnik is an independent and highly specialized medical device manufacturer, focused on developing innovative (robotic) solutions for micro invasive interventions. iSYS offers a competitive superiority through unique technology, combined with accessories for active and passive image-guided naviga-tion. In this novel approach, a small, modular robotic system is integrated into existing and future technologies. This will allow image-guided interventions to become not only more precise but also more efficient and less invasive, leading to improved user and patient safety and therapeutic outcomes.

Company Profile


Management Team

CEO: Michael VogeleCFO: Thomas Pfeifer

Public Funding

aws (PreSeed, Seed, Double Equity): € 1.75MOthers (CAST): € 50,000

Private Funding

€ < 1.5M

Technology

— The iSYS 1 Interventional Platform is a modular needle guidance platform for interventional radiology and related fields.

— Core components are a 4 DOF Robotic Positioning Unit, which allows submillimet-ric needle positioning as well as angulation and a control unit that is controlled by a cable-connected Handheld Control Unit.

— The passive macro positioning unit and different table adapters allow different set-ups of the system around the patient in the region of interest while still providing maximum rigidity.

— The needle-guide-set provides dispos-ables that ensure precise & sterile needle guidance.

— Planning of the intervention is based on digital image data acquired intra-operative-ly using different kinds of modalities, like CT or 3D-fluoroscopy.

Market

— According to experts, the robotic market has great potential in several medical fields.

— Computer- and robot-supported systems are among the standard equipment of uni-versity hospitals today. Robotic systems are already being deployed in various med-ical fields such as orthopedics, radiology, and oncology.

— There is a special potential for robotics in oncology because of increasing cancer incidences and inefficient treatment methods.

— 24.6 million people suffer from cancer at the moment; the estimated number of new cancer incidences per year is expected to rise from 10.9 million in 2002 to 16 million by 2020.

— There are various cancer treatment meth-ods that can be significantly improved through the use of medical robots.


— iSYS 1 CB-CT Interv. Radiology, Oncology, Computer-Assisted Surgery

Class I, approved

— iSYS 1 ICT Interv. Radiology, Oncology, Computer-Assisted Surgery

Class I, approved

— iSYS 1 CT Navi+ Interv. Radiology, Oncology, Computer-Assisted Surgery

Class I, approval procedure

— iFix Interv. Radiology, Oncology, Computer-Assisted Surgery


— MTD Interv. Radiology, Oncology, Computer-Assisted Surgery


— SBP Interv. Radiology, Oncology, Computer-Assisted Surgery

Class I, approved

iSYS Medizintechnik GmbH

Bergwerksweg 216370 Kitzbühel, Tyrol, Austria+43 664 241 114 [email protected]

Products

iSys robotic solutions for micro invasive interventions

130 Medtech – 131

Jeder Easier dental implants by secure, minimally invasive sinus augmentation. The Jeder-System offers easy and secure sinus augmentation by using high hydraulic pressure and providing real-time feedback to the surgeon. One in four dental implants require prior bone grafting, with sinus augmentation being one of the most frequently performed grafting procedures. Bone mass is increased in the upper jaws of a patient by placing bone replacement material between the sinus membrane and the jaw bone.

Company Profile


Management Team

CEO: Andreas BayerleCSO: Michaela Bayerle-EderCTO: Klaus EderCMO: Philip Jesch

Public Funding

aws Seed: € 600,000Others (NÖBEG): € 400,000

Private Funding

Not disclosed

Technology

— For dentists and oral/maxillofacial sur-geons, the Jeder-System improves out-comes for sinus augmentation and pro-vides a simpler, easier-to-use system for the surgeon.

— Novel method of using high (1.5 bar) hydraulic pressure in a controlled way for a minimally invasive sinus augmentation

— Protected by 4 patent families in more than 30 countries

Market

— In 2010, more than 1 million dental implants were placed in Germany. Of those, 25% needed some form of bone grafting.

— Globally, there are more than 100,000 implantologists placing some 6 million dental implants annually.


— Jeder-System Minimally in-vasive bone grafting for placing dental implants

Class IIa, approved

Jeder GmbH

Starkfriedgasse 621190 Vienna, Austria+43 1 4700 [email protected]

Products

The Jeder technology

132 Medtech – 133

Lacerta Technologies is a regenerative medicine company that aims to translate research results into products for routine clinical use. We place special emphasis on designing simple and affordable protocols to allow a wider patient population to benefit from cell therapy.

Company Profile


Management Team

CEO: Zsombor LaczaCFO: Björn Ehring

Public Funding

aws Seed: € 750,000Others (ACCENT): € 50,000

Private Funding

€ 75,000

Technology

— Serum-albumin-coated bone grafts. An off-the-shelf bone substitute, which has most of the benefits of stem cells and growth factors without their cost and complexity. It induces the patient’s own stem cells to proliferate, resulting in fast remodeling of the graft.

— GraftBuilder Stage 1. A point-of-care device for isolating a proprietary growth factor mix (serum from platelet-rich fibrin) from the patient’s blood. Ready to be reapplied in 15 minutes in orthope-dics and sports surgery indications.

— GraftBuilder Stage 2. A custom-made bone graft system for specialized clinics and tissue banks. It is capable of cre-ating personalized bone graft coatings for demanding cases where inducing bone formation and fighting bacterial infection are both necessary.

— IP: 1 granted and 4 pending patents

Market

— Bone is the second-most-frequently transplanted human tissue. Due to the limited availability and complications in harvesting autografts, a variety of bone graft substitutes (allografts, growth fac-tors, cell-, ceramic-, or polymer-based grafts) has been developed. Today, they represent a global industry of $ 2.5bn annually, with the US being by far the largest market with more than 1 mil-lion grafting procedures performed annually. The two professions that use the majority of bone grafts are ortho-pedic and dental surgeons, facing the problem of a lack of suitably strong bone to support a metal implant. Lacerta’s market niche is improved bone grafts that support the patient’s own stem cells to regenerate the tissue and fight bacterial infection to preserve the graft.


— Albumin bone graft Dental, orthopedic, off-the-shelf

Tissue product, first-in-human

— Antibiotic bone graft Dental, orthopedic, off-the-shelf

Drug-device combination, preclinical

— GraftBuilder Stage 1 Sports and orthopedic surgery, point-of-care

Class IIa, lab prototype

— GraftBuilder Stage 2 Orthopedics, personal-ized graft

Class IIa, preclinical

— Imaging Chamber Live cell microscopy Lab device, prototype

Lacerta Technologies GmbH

Dr. Karl-Dorrek Str. 23-293500 Krems an der Donau, Lower Austria, Austria +43 664 883 162 [email protected]

Products

Lacerta Team and Technology

134 Medtech – 135

medizinkraft solutions develops an integrated system (hardware and software) for applications in the treatment of musculoskeletal disorders using remote sensing technologies (temperature, depth, RGB). By aggregating the sensor data, a precise 3D representation of the body is generated in real-time, allowing an accurate determination of the skeleton and motion tracking, which is used in diagnostic as well as in thera-peutic contexts.

Company Profile

Founded: 2012Legal Form: GmbH & CO KGEmployees: 11

Management Team

CEO: Christian KocourekCMO: Michael MatznerCTO: Peter Marksteiner

Public Funding


Technology

— “MotionAid,” the product developed by medizinkraft solutions, is an embedded system that integrates several sensors and a high-performance single-board computer in a single box. It requires no other local infrastructure than a TV set with an HDMI interface. It is operated and controlled remotely by gestures.

— MotionAid is a class Im medical device compliant with IEC 62304, ISO 13485, and ISO 14971.

Market

— In the first step, MotionAid will be launched in the German-speaking countries (D-A-CH region) for sup-porting diagnosis and rehabilitation after total knee (TKR) and total hip replacement (THR).

— In 2010, a total of 191,845 TKR and 249,281 THR operations were per-formed in the D-A-CH region; the number is steadily increasing.


— MotionAid Musculoskeletal disorders Class Im, under development

medizinkraft solutions GmbH & CO KG

Dr. Franz-Wilhelm-Straße 23500 Krems an der Donau, Lower Austria, Austria+43 1 403 991 [email protected]

Products

medizinkraft Management Team: Michael Matzner, Christian Kocourek and Peter Marksteiner

136 Medtech – 137

Murmur Detect provides medical professionals with clinically proven tools for the detection of pathological heart conditions with an emphasis on automated, non-invasive products that yield fast, reliable, diagnosis-assisting results right at the patient’s side.

Company Profile

Founded: Planned for 2014Legal Form: GesmbH light

Management Team

CEO, co-founder: Andreas Schriefl CSO, co-founder: Andreas Reinisch

Public Funding


Private Funding

€ 26,000

Technology

— Background: Newborns demand special medical attention and protection. One rou-tine examination is the auscultation of the heart with a stethoscope, a well-established and standardized method performed by doctors worldwide wherein they distinguish between “normal” and pathological heart sounds. Fast heartbeats, the unsettled and agitated behavior of the babies, and a fre-quently noisy hospital environment make a successful diagnosis particularly challeng-ing. If diagnosed too late, or in a worst-case scenario diagnosed incorrectly, a whole spectrum of serious consequences can arise.

— Technology: Murmur Detect developed algo-rithms capable of analyzing heart sounds fully automated. Based on superior, pat-ent-pending technologies, Murmur Detect provides tools for medical professionals to assist them in detecting and diagnosing clinically relevant heart conditions, based on well-defined scientific criteria. The algo-rithms are fast and can be utilized right at the patient’s side, without interfering with the clinical routine. The results are fewer false diagnoses and the earlier detection of heart murmurs, leading to more efficiency and effectiveness in the medical treatment of newborns; time saved for the medical

staff; a reduction in unnecessary follow-up examinations; and, in turn, to long-term cost reductions for the medical system.

Market

— Market Segments: Based on different med-ical needs between patient groups, Murmur Detect develops specialized tools tailored to patient requirements: Infant system: for pre-mature babies and newborns; Pediatric sys-tem: for children; Adult system: for adults, aged 50+

— Market Volumes: Murmur Detect algorithms can be utilized in combination with electron-ic stethoscopes. The global stethoscope market volume in 2017 is estimated to be € 263M.

— Currently, Europe and the USA comprise the biggest markets, while Asia shows the high-est growth rate with +4.5% per year, espe-cially in the electronic stethoscope segment at the expense of mechanical stethoscopes.

— Potential end users of Murmur Detect tools include: nurses, nurse practitioners, physi-cian’s assistants, midwives, neonatologists, cardiologists, pediatricians, family doctors, medical responders, Red Cross employees, NGOs, general practitioners, etc.


— Heart murmur detection assistant

Automated auscultation assistant

IIa, under development

Murmur Detect

Plüddemanngasse 398010 Graz, Styria, Austria+43 660 6555 [email protected]

Products

Murmur Detect technology


mySugr is an m-health service company that focuses on making the life of diabetics easier and more fun. We specifically target the motivation component of diabetes treatment.

Company Profile


Management Team

CEO: Frank WestermannCSO: Gerald Stangl

Public Funding

aws Seed: € 750,000aws PreSeed: € 149,000Others (Impulse XL): Not disclosed

Technology / Innovation

— Smart logbook: Clever, fast, and valu-able logging. The smart phone enriches manually entered data with automatically generated information.

— Gamification: We will create a positive feedback culture through game chal-lenges. We reward action and ultimately visualize therapy progress.

— Caring and sharing: We will be matching up diabetics with corresponding therapy patterns to stimulate positive behavior.

— Compliance: The application aids com-pliance through the use of motivational triggers. It gives feedback on the cur-rent therapy state and rewards diabetics striving for therapy compliance. This leads to the user being aware of the positive effects of therapy and supports awareness.

Market

— 350M diabetics worldwide — € 137bn spent annually by European

health care on patient treatment — 20% increase in Europe by 2030 — 73% of diabetics do not log their data


— mySugr Companion The logbook is a powerful and important tool to help people with diabetes (PWD) to self-manage their disease. The Companion is a charming, sometimes outspoken dia-betes manager. The app has a similar purpose to a diabetes logbook. It provides immediate feedback and helps people with diabetes to stay motivated.

— mySugr Junior Managing day-to-day life with diabetes is a challenging task, especially for the little ones. mySugr Junior is a smart logbooking app that helps children, who still need their parents’ support, to master this great challenge day by day. mySugr Junior not only makes it possible for our little ones to be more independent in their carefree day-to-day life, but it also teaches them in a playful way how to deal with their diabetes.

mySugr GmbH

Siebenbrunnengasse 441050 Vienna, Austria+43 699 [email protected]

Services

The mySugr Service

140 Medtech – 141

ScarletRed focuses on emerging technologies in the field of biomedical engineering to develop innovative products for state-of-the-art medical diagnostics and therapy. After successful proof of concept of its lead medical device candidate (SCR001), substantial PreSeed funding could be gained to secure CE marking. The novel technology enables objective remote visual assessment of drug and treatment efficacy by providing a real-time data link between trial sponsor and local physicians. This positively impacts the process of clinical testing by reducing time, risk, and opportunity costs. Technology leadership and first-mover advantage provide a significant competitive edge for the startup to enter the global market.

Company Profile

Founded: 2013Legal Form: GmbH i.G.Employees: 4

Management Team

CEO: Harald Schnidar

Public Funding

aws PreSeed: Not disclosedOthers (FFG Innovation-Scheck): Not disclosed

Private Funding

Not disclosed

Technology

— Prototype developed during phase 1b safety and efficacy testing of an IND in irradiated cancer patients

— Remote and standardized single/multi-centric clinical observations of epithe-lial areas without physical contact with inflamed, damaged, or infectious areas

— GCP-compliant anonymization and blinding of medical data according to international IHC standards

— Device works wireless and independent of location

— Compatible with smart phones and tablet computers

Market

— Global clinical drug testing market — Remote patient monitoring: € 27M

(2013) – € 50M (2017), CAGR 16.5% — Acute and chronic wound care market:

€ 16bn (2011) – € 23bn (2016); CAGR 7.3% — Cancer irradiation incidence rate 2012:

Breast/HNC irradiation: 2.3M — Dermatologic drug testing: Acne

(cosmetics, cancer therapy): 82M, Atopic dermatitis: 240M

Products Stage of development

— SCR001 eMedical device (class IIa); clinical testing for CE mark

— License By fee for use according to EULA

— Patent Filed 2013 by international prio-application

ScarletRed Biomedicals GmbH i.G

Würffelgasse 4 T661150 Vienna, Austria+43 664 885 062 [email protected]

Products

Services

— App for objective analysis of erythema and wound healing

— Electronic medical data processing center

— Clinical trial design and consulting — Biostatistics report

ScarletRed technology

142 Medtech – 143

SIMCharacters develops pediatric patient simulators. The convincingly life-like simulators enable a previously unattainable degree of effectiveness to be achieved during simulation-based training sessions in medicine. The medical care of a critically ill child is a rare event, even for the majority of pediatricians. If the right steps are not taken during treatment, this can have a life-long impact on the further development of the child. The SIMCharacters patient simulators combine modern technology, making it possible to simulate pathol-ogies and extremely realistic internal and external anatomy for the first time. This helps health care professionals to save children´s lives.

Company Profile


Management Team

- CEO: Jens-Christian Schwindt- Finance: Michael Hoffmann- R&D: Ewald Unger- Art Director: Christoph Kunzmann

Public Funding

aws PreSeed: € 220,000Others (PRIZE): € 150,000

Private Funding

€ 20,000

Technology

— SIMCharacters combines a high degree of technical expertise in the realistic implementation of previously unsimu-latable pathologies by means of minia-turization and the development of com-pletely novel simulation components (e.g. breathing-related pathologies). This results in high-fidelity pediatric patient simulators.

— SIMCharacters holds patents on several simulator-related components.

Market

— Customers: Simulation centers (public and privately owned), Universities, Teaching hospitals.

— Market potential focused market seg-ment: € 95M p.a.

— Market growth focused market: 15% – 20% p.a. (Europe, US, Asia)

— SIMCharacters targets the worldwide market of simulation technology

SIMCharacters GmbH

Geblergasse 66/101170 Vienna, Austria+43 699 196 898 [email protected] www.simcharacters.com

Products

SIMCharacters pediatric patient simulators

Products Stage of development

— SIMCharactersPreterm Under development

144 Medtech – 145

TissueGnostics is an innovative R&D company that develops and sells best-in-class systems for use in scientific research and routine diagnostics. The company was founded in 2003 based on preceding academic development at the Medical University of Vienna and has subsidiaries in Romania and the USA. With 140+ unique installation sites and 270+ total software licenses in Europe, North America, Asia, and the Middle East and 100+ scientific publications, the company is well perceived within the international scientific community.

Company Profile

Founded / 2003Legal Form / GmbHEmployees / 31

Management Team

CEO/CSO / Georg Steiner CEO/CFO / Rupert Ecker

Public Funding

(aws Seed, aws Double Equity, EU Grants, ZIT, FFG, WWTF): € 4.3M

Private Funding

€ 2.833M

Technology

— High-speed scanning technology for brightfield and fluorescence slides as well as culture plates

— Automated workflow from single slide systems up to 200 slides or 20 cul-ture plates, high-throughput imaging platforms

— IVD conform image analysis suitable for pathology and hematology as well as cancer and clinical research

— HistoQuest for histopathology has been used extensively in the fields of cancer research and immunology.

— TissueQuest is a suite for the simulta-neous phenotypic and functional char-acterization of cells with several markers as well as FISH analyses.

— StrataQuest is a new multilayer image processing platform for automating

the complex multistep analysis that is needed in routine pathology and basic research.

— HemoQuest is a new multifunctional SW for automatic classification of leuko-cyte subsets in blood and bone marrow smears and body fluids.

Market

— TissueGnostics innovative products address 4 different market segments. Segment / 2011 / CAGR 2011-2016

— IVD / $ 44bn / +7.8% — Cell & Tissue analysis / $ 6.9bn / +9.6% — Digital Pathology / $1.9bn / +12% — Hematology / $ 5.7bn / +5%

Products Description

— TissueFAXS Cancer research, Immunology, FISH, TMA, Cell culture analysis

— HistoFAXS Immunohistochemistry, Histology, Basic scientists, TMA

— PathoFAXS Routine pathologists, including fully automated and clinically tested analysis profiles and reports

— HemoFAXS Hematology and laboratory medicine

— StrataFAXS A new generation of interactive high-speed scanning and analysis platform

TissueGnostics GmbH

Taborstrasse 10/2/81020 Vienna, Austria+43 1 2161190 [email protected]

Products

Tumor cells (in red) within a distance of 10 µm of the next blood vessel (close tumor cells in green, and blood vessels in gray)

146 Medtech – 147

Tyromotionis one of the worldwide leading providers of robotics and computer-aided therapeutic devices in the area of neuro and orthopedic rehabilitation. The product portfolio includes tailor-made solutions for the upper extremities, especially for hand, arm, and finger rehabilitation. The company‘s focus is on the development of new technologies of high-performance mechatronic systems in rehabilitation. The sales network extends to 30 partners across the globe. Tyromotion cooperates in the development of therapy devices with renowned research partners such as the Columbia University in New York or the Johns Hopkins University in Baltimore.

Technology

— Robot- and computer-aided therapy devices for upper-extremity rehabilitation.

Tyromotion product


— Amadeo® Finger, hand rehabilitation Approved

— Pablo® Hand, arm rehabilitation Approved

— Tymo® Hand, arm rehabilitation Approved

— Diego® Arm rehabilitation Approval procedure

— tyrostation Workstation for Tymo & Pablo Approved

Products

Company Profile


Management Team

CEO: Ram DavidCEO: Alexander Kollreider

Public Funding

aws PreSeed: € 77,000others: not disclosed

Private Funding

not disclosed

Tyromotion GmbH

Bahnhofgürtel 598020 Graz, Styria, Austria+43 316 908 [email protected]

Market

— Primarily Tyromotion targets the Western European, Asian, and American markets with 1.2 million stroke patients a year, of which about 25% are eligible for hand exercising therapy

148 Medtech – 149

VASCOPS develops new A4clinics software screens for patients at high risk of life-threatening vascular rupture. The ballooning of a blood vessel is referred to as an aneurysm. If this occurs in the aorta and this subsequently ruptures, the consequences are immediately fatal. The novel A4clinics software from VASCOPS supports physicians who have to make patient-specific risk assessments by allowing rapid screening and detection of patients at highest risk of rupture.

Company Profile


Management Team

CEO: Carmen GasserCTO: Thomas Christian GasserCSO: Martin Auer

Public Funding

aws PreSeed: € 100,000aws Seed: € 500,000others (Science Park Graz): € 52,200

Technology

— Localized ballooning of the abdominal aorta is a predominant risk factor for aortic rupture, which may lead to death within minutes.

— VASCOPS develops software programs based on CT data that generate images within a few minutes, showing pressure of the vascular wall.

— This patient-tailored imaging technology allows quick and qualitative AAA rupture risk assessment, thereby providing data that support the decision making for surgical interventions.

— Legal protection is given in terms of holding international patents to protect all novel algorithmic steps.

Market

— Despite the implementation of different health care programs, cardiovascular diseases are still the main cause of death in the Western world.

— 6% of the European population is affected by AAA, necessitating approxi-mately 50,000 examinations a year.

— Numbers are increasing due to AAA screening programs and an aging population.

— There is no comparable AAA rupture risk assessment method on the market assuming high market volume potential.


— A4clinics Medical software Class IIb, approved

— A4clinics Research Edition

Medical research software

Class IIb, approved

— TAA (Thoracic Aneurysm Analyzer)

Software to define the rupture risk of thoracic aortic aneurysms

Class IIb, preclinical

— CPVA (Carotid Plaque Vulnerability Analyzer)

Software to define the rupture risk of carotid plaques


— GP (Growth Predictor) Software to compute the growth of AAA by a diagnostic prognosis


VASCOPS GmbH

Plüddemanngasse 398010 Graz, Styria, Austria+43 660 765 513 [email protected]

Products

Vascops technology

150 Medtech – 151

VASEMA is an ISO 13485 manufacturer of high-tech medical devices designed for skin diagnostics. The first class IIa product – dermaMeter® professional 100 – represents a real mile-stone in this area. The company’s objective is to provide solutions for the global challenges concerning skin health.

Company Profile


Management Team

CEO, founder: Peter Hagl

Public Funding

aws PreSeed: € 170,000aws Seed: € 750,000departure focus design: € 162,191INiTS: € 27,900

Private Funding

€ 659,290

Technology

— For the first time in the history of skin diagnosis, everyone can measure their skin health through the TEWL-value (transepidermal water loss) objectively and reliably within a few seconds.

— The dermaMeter® is wireless, easy to use and always ready for use; hygiene caps meet the highest hygiene stand-ards and guarantee a safe and sterile measurement.

— VASEMA holds patents on technology and applications, the trademarks, and the designs.

Market

— Due to increasing life expectancy, chem-ical, physical, and psychological stress factors, and people’s growing health consciousness, skin diseases are on the rise and prevention of diseases is get-ting more and more important.

— The market for our products has been evaluated by a number of active physi-cians in seven selected European coun-tries. In these countries alone, there is a potential of € 1.5bn with an annual growth rate of 19%.

— VASEMA’s first target market will be Europe and the Middle East.


— dermaMeter® Skin diagnosis and monitoring

Class IIa, approved

— dermaMeter® – Hygiene cup Sterile measurement Class IIa, approved

— Apps Data handling Class I, under development

— dermaMeter® Rheumatism Class IIa, under development

VASEMA GmbH

Brunner Straße 67 / 41230 Vienna, Austria+43 1 890 [email protected]

Products

Vasema product dermaMeter®

aws Temporary Management

Financing of complementarymanagement expertisewww.awsg.at/maz

aws PreSeed

Financing the pre-start phasewww.preseed.at

aws Seedfinancing

Financing the start-up phase of life science companieswww.seedfinancing.at

We bringLife Sciences

to Life

50.000 Euro

200.000 Euro

1.000.000 Euro

www.lifescienceaustria.at

aws best of biotech

International Biotech & Medtech Business Plan Competition

www.bestofbiotech.at

get your

businessstarted!

3 × 1,500 Euro

Business Idea

Phase 1 2.6. – 27.11.2014

10,000 Euro

LISAvienna

Medtech Award

1. 15,000 Euro 2. 10,000 Euro 3. 5,000 Euro

Business Plan

Phase 2 28.11.2014 – 6.5.2015

Advancing Austrian life science at the heart of Europe

www.LifeScienceAustria.at

LISA_ANZ_148,5x210mm_SLOGAN_RZ.indd 1 01.10.13 11:52

aws best of biotech



get your

businessstarted!

3 × 1,500 Euro

Business Idea

Phase 1 2.6. – 27.11.2014

10,000 Euro

LISAvienna

Medtech Award

1. 15,000 Euro 2. 10,000 Euro 3. 5,000 Euro

Business Plan

Phase 2 28.11.2014 – 6.5.2015

aws best of biotech



get your

businessstarted!

3 × 1,500 Euro

Business Idea

Phase 1 2.6. – 27.11.2014

10,000 Euro

LISAvienna

Medtech Award

1. 15,000 Euro 2. 10,000 Euro 3. 5,000 Euro

Business Plan

Phase 2 28.11.2014 – 6.5.2015

aws Life Science

Portfolio Austrian Life Science Companies

2013aws

Lif

e S

cience

Austria Wirtschaftsservice Gesellschaft mbH Walcherstraße 11A 1020 ViennaT +43 1 501 75-100 E [email protected] www.awsg.at

aws Lisa Porfolio 2013

Documents

Transcript of aws Lisa Porfolio 2013